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	ABSTRACT		
	
Clostridium	difficile	infection	(CDI)	is	one	of	the	most	commonly	reported	
hospital‐associated	infections	in	the	U.S.,	causing	to	around	500,000	infections	
and	29,000	deaths	each	year.		This	dissertation	describes	the	results	of	three	
different	studies	exploring	the	role	of	the	host	and	pathogen	on	CDI	severity.		
For	the	first	study,	200	successive	CDI	positive	stool	samples	were	
collected	from	the	Microbiology	Laboratory	at	Saint	Joseph	Mercy	Hospital.		Fecal	
toxin,	spore,	and	Candida	albicans	levels	were	quantified	to	characterize	the	in	
vivo	association	between	toxin	and	spore	levels	and	whether	this	association	was	
modified	by	C.	albicans.		Results	indicate	a	strong	association	between	toxin	and	
spore	levels	within	the	human	CDI	host,	with	the	association	varying	by	ribotype.		
C.	albicans	overgrowth	did	not	modify	this	association.		
We	next	performed	a	case‐control	study	comparing	120	toxin	positive	CDI	
and	91	toxin	negative	PCR	positive	CDI	hospitalized	patients.		We	described	
clinical	and	epidemiological	differences	between	CDI	patients	according	to	their	
laboratory	diagnosis.		In	a	population	with	92%	CDI	treatment	rate,	we	
confirmed	a	milder	CDI	presentation	and	lower	30‐days	risk	of	mortality	among	
toxin	negative	PCR	positive	patients.		Furthermore,	spore	levels	were	associated	
with	CDI	severity.		These	results	highlight	a	major	limitation	of	using	PCR	in	the	
CDI	laboratory	algorithm	and	the	importance	of	the	severity	of	the	patient’s	
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clinical	presentation	when	considering	treatment	for	a	patient	testing	as	toxin	
negative	PCR	positive.			
Lastly,	we	used	an	in‐host	mathematical	model	to	characterize	the	role	of	
sporulation/germination	patterns	on	risk	of	recurrence	and	compare	the	
effectiveness	of	several	current	tapered/pulsed	vancomycin	regimens	on	risk	of	
recurrence	by	specific	ribotypes.		Our	results	confirm	the	importance	of	C.	
difficile	ribotype	in	explaining	CDI	recurrence	rates	and	the	effectiveness	of	
treatment.		All	of	the	evaluated	treatment	regimens	for	repeated	CDI	were	
effective;	further,	regimens	with	reduced	duration	or	dosage	of	treatment	were	
still	highly	effective,	suggesting	that	vancomycin	regimens	may	be	modified	to	a	
lower	level	that	better	protects	gut	microbiota	while	preventing	CDI	recurrence.			
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CHAPTER	I		
Introduction	
	
	 Clostridium	difficile	infection	(CDI)	is	currently	the	most	prevalent	
healthcare	associated	infection	(HAI)	in	the	United	States	(US)	(1).		Every	year	
approximately	half	a	million	infections	and	29,000	deaths	are	attributed	to	
C.difficile	(2).		Due	to	its	high	incidence	and	mortality	rate,	and	its	reported	
associated	excess	healthcare	cost	of	4.8	billions	dollars,	hospital‐associated	CDI	
rates	are	now	used	as	an	indicator	of	healthcare	quality	(3).		As	a	further	
indication	of	its	public	health	significance,	in	March	2015	the	White	House	set	a	
national	goal	to	reduce	CDI	by	50%	by	2020	(4).			
Although	much	has	been	learned	about	the	pathogenicity	and	
transmission	of	CDI,	managing,	controlling,	and	preventing	CDI	in	healthcare	
settings	remains	a	challenge.		One	such	challenge	includes	the	lack	of	an	accurate	
diagnosis	of	CDI	symptomatic	patients	in	order	to	correctly	differentiate	them	
from	C.	difficile	carriers	and	to	customize	their	management,	infection,	and	
control	practices	accordingly.		This	dissertation	addresses	this	challenge,	
particularly	identifying	differences	between	CDI	positive	patients	based	on	
according	to	the	laboratory	algorithm	used	for	diagnosis,	including	differences	in	
their	pathogenicity	and	sporulation	patterns	in	vivo.		
The	remaining	chapters	of	the	dissertation	are	as	follows:		Chapter	2	
describes	the	epidemiology	of	CDI,	and	highlights	its	significance	as	a	public	
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health	problem.		Chapter	3	presents	the	results	of	a	laboratory	analysis	of	stool	
samples	from	CDI	cases	aimed	at	characterizing	the	in	vivo	correlation	of	C.	
difficile	spore	and	toxin	production,	and	testing	whether	this	correlation	is	
mediated	by	Candida	albicans.		In	Chapter	4	a	compartmental	in‐host	
mathematical	model	is	used	to	analyze	the	ribotype‐specific	effectiveness	of	
recommended	tapered/pulsed	vancomycin	regimens,	to	gain	insight	into	the	
importance	of	varying	sporulation	patterns	across	ribotypes	in	the	risk	of	CDI	
recurrence.	Chapter	5	describes	differences	in	risk	factors,	severity,	and	clinical	
outcomes	between	toxin	positive	and	toxin	negative/PCR	positive	CDI	patients.		
This	chapter	also	identifies	hosts’	risk	factors	associated	with	spore	production	
in	vivo.		Chapter	6	concludes	the	dissertation	with	a	discussion	of	the	
implications	of	the	results	for	future	research,	treatment,	and	infection	control.			
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CHAPTER	II	
Background	and	Significance	
	
Clostridium	difficile	is	an	anaerobic,	spore‐forming,	Gram‐positive	bacillus	
found	in	nature	as	either	toxigenic	or	non‐toxigenic,	based	on	the	presence	or	
absence	respectively	of	the	pathogenicity	locus	(PaLoc)	that	encodes	for	genes	
associated	with	toxin	production	(1,	2).	Although	approximately	5%	of	healthy	
adults	and	30‐70%	of	healthy	infants	carry	toxigenic	C.	difficile	asymptomatically	
(3),	toxigenic	strains	are	also	associated	with	Clostridium	difficile	infection	(CDI),	
a	broad‐spectrum	toxin‐mediated	intestinal	disease	(4,	5).		
CDI	causes	significant	morbidity	and	mortality,	greatly	increasing	
healthcare	costs.		In	March	2015	the	White	House	included	CDI	reduction	in	its	
national	goals	(6).		This	chapter	consists	of	a	comprehensive	literature	review	of	
the	CDI’s	epidemiology,	pathogenicity	and	transmission,	and	its	public	health	
significance.			
	
2.1.0.	Epidemiology		
	
2.1.1.	Clostridium	difficile	Infection	(CDI)	burden			
	
CDI	was	initially	described	in	1978	(7).		While	at	first	CDI	was	considered	
a	rare	infection,	today	12.1%	of	all	reported	nosocomial	infections	are	CDI,	
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making	C.	difficile	the	most	commonly	reported	nosocomial	pathogen	(8).		
Between	2001	and	2010,	CDI	incidence	nearly	doubled	in	the	United	States	(US)	
(6),	reaching	almost	half	of	a	million	infections	and	29,000	associated	deaths	in	
2011	(9).		However,	possibly	due	to	increased	awareness,	during	the	last	five	
years,	CDI	incidence	has	started	to	plateau	and	even	decrease.		In	2015,	Centers	
for	Disease	Control	and	Prevention	(CDC)	reported	the	number	of	CDI	cases	in	US	
hospitals	decreased	10%	between	2012	and	2013	(10).		
The	high	CDI	incidence	and	associated	morbidity	and	mortality	(11)	
places	a	significant	financial	burden	on	the	US	healthcare	system.		In	acute‐care	
settings	alone,	excess	healthcare	costs	associated	with	CDI	total	an	estimated	4.8	
billion	dollars	every	year	(5,	12,	13).	Each	CDI	episode	is	estimated	to	cost	up	to	
$7,000	(14),	increasing	hospital	costs	for	a	CDI	patient	by	54%	(15).		In	addition,	
length	of	hospital	stay	may	increase	up	to	12	days	(9,	16).	Furthermore,	
institution	of	proper	infection	control	procedures	including	patient	isolation,	use	
of	contact	precautions	and	personal	protective	equipment	can	reduce	incidence	
and	spread	within	hospitals;	therefore,	hospital‐associated	CDI	rates	are	
currently	used	as	an	indicator	of	healthcare	quality	(17).	
	
2.1.2.	Epidemiological	classification	of	CDI	cases		
	
The	change	in	CDI	epidemiology	over	time	has	also	affected	populations	
previously	considered	low‐risk	for	CDI.		An	increasing	number	of	cases,	including	
severe	ones,	have	been	reported	in	pregnant	women	and	healthy	community	
members	(18).		To	facilitate	CDI	surveillance	and	research,	the	CDC	recommends	
classifying	CDI	cases	by	previous	healthcare	exposure	and	time	of	onset	of	CDI	
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symptoms	as	follows:	1)	Healthcare	facility	(HCF)‐onset	and	HCF–associated	
when	the	onset	of	symptoms	occurred	more	than	48	hours	after	admission	to	a	
HCF,	2)	Community‐onset,	HCF‐associated	when	either	the	patient’s	symptoms	
started	48	hours	or	less	after	admission,	or	in	the	community	but	less	than	4	
weeks	after	being	discharged	from	a	HCF,	3)	Community‐associated	when	either	
the	patient’s	symptoms	started	48	hours	or	less	after	admission,	or	in	the	
community,	but	after	more	than	12	weeks	after	discharge	from	a	HCF,	4)	
Indeterminate	when	exposure	setting	is	hard	to	establish,	for	example	if	the	
patient	was	discharged	from	a	HCF	between	4	and	12	weeks	before	onset	of	
symptoms,		and	finally,		5)	Unknown	disease	when	data	are	not	available	to	define	
exposure	(19).			
Based	on	this	classification,	Lessa	et	al.	(2015)	have	estimated	a	total	of	
159,700	community‐associated	CDI	cases,	in	comparison	to	293,300	hospital‐
associated	CDI	cases	in	the	US	for	2011.		Of	the	hospital‐associated	CDI	cases,	
37%	had	a	hospital‐onset,	36%	had	a	nursing	home	onset,	and	28%	had	a	
community‐onset	(9).			
	
2.1.3.	Prevalent	strains	
	
Several	different	strains	of	C.	difficile	have	been	identified,	which	vary	in	
pathogenicity,	virulence	and	transmissibility.		Currently	in	the	US,	the	most	
prevalent	strains	are	North	American	pulsed‐field	(NAP)	1,	NAP4,	NAP6,	NAP7,	
NAP11,	which	represent	PCR	ribotypes	027,	014‐020,	002,	078,	and	106	
respectively	(9).		
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	Of	greatest	public	health	concern	is	ribotype	027.		Since	2003,	ribotype	
027	(NAP1,	Toxinotype	III,	Restriction	endonuclease	analysis	(REA)	B1)	has	
caused	several	outbreaks	of	severe	CDI	in	Canada,	Europe,	and	the	US	(1).		Over	
time,	ribotype	027	isolates	have	become	increasingly	virulent	compared	to	
historical	027	strains	or	other	C.	difficile	strains	(1).		The	increases	in	
pathogenicity	and	transmissibility	are	attributed	to:		1)	higher	toxin	production,	
2)	resistance	to	fluoroquinolones	and	erythromycin	that	complicates	treatment	
and	favors	its	selection	in	healthcare	settings,	and	3)	greater	amount	of	spores	
produced	(1,	13,	20‐23).	
	
2.1.4.	Risk	Factors	
	
As	the	number	of	C.	difficile	carriers	increases,	it	is	essential	to	recognize	
that	colonization	with	bacteria	is	not	sufficient	for	development	of	CDI.		Virulence	
factors	from	the	infecting	C.	difficile	strain,	the	host’s	gut	microbiota	composition,	
and	other	host‐associated	factors	play	a	role	in	the	initiation	of	symptoms	(4).		
Prior	antibiotic	use	is	the	leading	risk	factor	for	CDI	(24).	Individuals	have	a	7	to	
10‐fold	increase	risk	of	developing	CDI	while	on	antibiotic	therapy	or	within	one	
month	of	completing	the	regimen	(25).		The	antibiotics	most	commonly	
associated	with	CDI	are	fluoroquinolones,	third‐	and	fourth‐generation	
cephalosporins,	ampicillin,	and	clindamycin	(24).		Other	risk	factors	include	
advanced	age,	exposure	to	the	healthcare	system	(including	outpatient	facilities),	
immunosuppressant	therapy,	use	of	proton‐pump	inhibitors	(PPIs),	
gastrointestinal	tract	surgery,	inflammatory	bowel	disease,	and	enteral	tube	
feeding	(1,	9,	24).	
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Antibiotic	treatment	is	associated	with	CDI	development	because	it	
disrupts	the	gut’s	microbiota	community	structure.		Changes	in	diversity	and	
composition	of	the	healthy	fecal	microbiota	create	an	environment	that	permits	
C.	difficile	overgrowth.		Bile	metabolism	and	food	competition	have	been	
reported	as	two	essential	mechanisms	leading	to	colonization	resistance	or	lack	
thereof	(26).		Shaninas	et	al.	(2012)	showed	that	a	healthy	balance	of	
Bacteriodetes	and	Firmicutes	is	necessary	to	avoid	C.	difficile	from	proliferating	
(27).		Likewise,	highly	infectious	colonized	individuals	known	as	supershedders	
have	reportedly	a	microbiota	mostly	composed	of	Escherichia	coli,	Proteus	
mirabilis,	Klebsiella	pneumonia,	and	Enterococcus	faecalis	(28).		Interestingly,	
Skraban	et	al.	(2013)	found	no	difference	in	fungal	diversity	in	the	gut	between	C.	
difficile	colonized	and	non‐colonized	individuals	(29).		However,	this	same	study	
found	that	CDI	patients	colonized	with	ribotype	027	were	more	likely	to	be	
colonized	with	Candida	albicans	and	Candida	glabrata	than	healthy	individuals	
(29).			
Candida	spp.	is	considered	a	gut	commensal.		Its	colonization	frequency	
ranges	from	4‐88%	in	healthy	individuals	but	is	generally	at	low	levels	(≤104	
CFU/mL)	(30).		Supporting	the	conclusions	of	Skraban	et	al.	(2013)	(29),	some	
researchers	suggest	the	prevalence	of	Candida	spp.	is	increased	among	CDI	
positive	patients,	and	that	colonization	might	positively	or	negatively	mediate	
risk	of	CDI	symptoms	(31‐33).		In	a	double‐blind,	randomized,	phase	III	clinical	
trial	in	multiple	hospitals	in	the	US	and	Canada,	Nerandzic	et	al.	(2012)	reported	
16%	Candida	spp.	positivity	among	301	CDI	patients	before	initiation	of	CDI	
treatment.		Manian	et	al.	(2013)	reported	17%	Candida	spp.	overgrowth	among	
60	American	CDI	cases	(31,	32).	In	contrast,	Raponi	et	al.	(2014)	identified	83%	
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Candida	spp.	colonization	among	40	CDI	positive	patients	at	hospital	Policlinico	
“Umberto	I”	in	Rome	(33).		
		In	2014,	Raponi	and	colleagues	described	a	positive	association	between	
Candida	spp.	and	CDI,	particularly	with	C.	albicans.		In	that	study,	61%	of	CDI	
positive	patients	(n=24)	were	colonized	with	the	yeast	in	contrast	to	34%	of	CDI	
negative	patients	(n=34)	(33).		By	contrast,	Manian	et	al.	(2013)	observed	a	
protective	association	between	C.	albicans	and	CDI,	where	overgrowth	of	C.	
albicans	was	significantly	less	likely	among	CDI	positive	patients	(10	of	60)	than	
CDI	negative	patients	(103	of	338)	(31).	One	question	for	the	current	study	is	to	
investigate	whether	the	presence	of	C.	albicans	is	associated	with	C.	difficile	spore	
and	toxin	production,	which	will	provide	further	evidence	to	evaluate	the	
association	between	both	microorganisms	in	the	gut.	
	
2.2.0.	Transmission		
	
C.	difficile	transmission	occurs	through	the	fecal‐oral	route.		C.	difficile	
spores	are	the	bacteria’s	transmissible	vehicle	(3).		Based	upon	mice	
experiments,	7	spores	per	cm2	is	estimated	to	be	sufficient	to	cause	transmission	
(1).		Spores	are	acquired	from	the	environment	when	shed	by	colonized	or	
infected	hosts	(4).		Approximately	50%	of	recovered	patients	continue	to	shed	
spores	into	the	environment	1‐4	weeks	after	CDI	treatment	(34).		
Spores	can	withstand	cleaning	and	desiccation,	and	can	be	shed	at	high	
rates.		Therefore,	in	the	absence	of	proper	hygiene	and	use	of	personal	protective	
equipment,	healthcare	workers	can	act	as	vectors	transmitting	CDI	within	
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hospitals.	Up	to	38%	of	CDI	cases	in	healthcare	settings	have	been	attributed	to	
healthcare	worker	transmission	(34).		With	the	purpose	of	reducing	this	role,	in	
2014	the	Society	of	Healthcare	Epidemiology	of	America	(SHEA)	recommended	
healthcare	workers	follow	a	set	of	dress	code	guidelines,	which	include	the	use	of	
short‐sleeves,	no	neckties,	jewelry	or	wristbands	while	in	clinical	practices	(35).		
Farrington	et	al.	(2010)	observed	that	a	“bare	below	the	elbows”	approach	
improved	hand	hygiene	effectiveness	(36).		Although	no	evidence	demonstrates	
the	effectiveness	of	not	using	neckties	in	reducing	nosocomial	pathogen	
transmission,	studies	have	isolated	pathogens	such	as	Staphylococcus	aureus	and	
Gram	negative	bacillus	from	physicians’	neckties	(37).			
In	addition	to	hospital	settings,	C.	difficile	has	been	isolated	from	soil,	hay,	
sand,	or	feces	from	cows,	horses,	dogs,	cats,	and	rodents	(38)		CDI	has	been	
reported	particularly	in	horses	but	also	in	pigs	and	calves	(2).		The	distributions	
of	prevalent	strains	among	human	and	animal	populations	overlap,	suggesting	
that	strains	can	transfer	between	humans	and	other	animals	(39,	40).		The	
prevalence	in	farm	animals	and	recent	isolation	of	C.	difficile	toxigenic	strains	
from	retail	food	products	suggests	that	foodborne	acquisition	may	be	an	
important	additional	mode	of	transmission	explaining	community‐associated	
infection	where	there	are	no	other	known	risk	factors	of	exposure	(40).			
Spores	are	resistant	to	the	acidic	environment	in	the	stomach.		Following	
exposure	to	the	appropriate	germinant,	they	germinate	into	vegetative	cells	in	
the	small	intestine	(3,	4).		The	spore’s	outer	surface	is	smooth	during	its	dormant	
state	but	during	germination	it	develops	filamentous	projections	that	attach	to	
the	colonic	microvilli	(1).		The	signaling	pathway	that	triggers	C.	difficile	
sporulation	and	its	environmental	cues	are	still	not	well	understood.		In	mice,	
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sporulation	starts	around	15	hours	after	infection	(41),	while	in	vivo	
transcriptome	analysis	in	monoxenic	mice	showed	that	sporulation	genes	are	
upregulated	as	early	as	4	hours	after	infection	(42).		The	transcription	factor	
Spo0A	is	known	as	the	master	regulator	of	sporulation	after	its	activation	by	
several	histidine	kinases.		Spo0A	then	activates	downstream	regulators	
associated	with	sporulation	while	repressing	others	related	to	vegetative	
functions	(43).		Starvation,	aerobic	environments,	or	quorum	sensing	are	also	
suspected	to	play	a	role	in	C.	difficile	sporulation	(43,	44).			
Subsequently,	C.	difficile	spore	germination	is	induced	by	the	presence	of	
taurocholate	and	glycine	(43).		Taurocholate	is	abundant	in	human	bile	and	is	
hydrolyzed	in	the	gut	into	secondary	bile	salts	(eg.	chenodeoxycholate),	which	
are	considered	inhibitors	of	spore	germination	(5,	43).		However,	mice	
experiments	have	shown	that	antibiotic	treatment	leads	to	a	higher	proportion	of	
primary	bile	salts	than	secondary	bile	salts	in	the	gut	promoting	C.	difficile	spore	
germination	and	vegetative	growth	leading	to	CDI	(43).	
	
2.3.0.	Pathogenesis	
	
Following	germination	in	the	small	intestine,	vegetative	cells	travel	to	the	
colon	where	they	multiply	and	colonize	the	gut’s	mucosa.		However,	in	
susceptible	individuals,	C.	difficile	is	able	to	penetrate	the	mucus	layer	and	adhere	
to	the	enterocytes	(1,	4,	5).		Susceptibility	could	be	mediated	by	the	presence	of	a	
protective	microbiota,	inactivation	of	germinant	molecules	by	
chenodeoxycholate	or	its	analogs	(45),	production	of	molecules	that	inhibit	C.	
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difficile		(46),	competitive	exclusion	from	the	microenvironment	by	non‐toxigenic	
strains(47),	and	occlusion	of	host	receptors	used	by	C.	difficile	(5).	
Toxin	synthesis	usually	occurs	in	response	to	nutrient	limitation,	but	
stress	and	catabolite	repression	can	also	enhance	toxin	production	(48).		For	
most	C.	difficile	ribotypes,	when	vegetative	cells	reach	the	stationary	growth	
phase,	they	start	the	synthesis	and	secretion	of	toxins	(4,	49).		By	contrast,	
ribotype	027	starts	producing	toxin	in	exponential	and	stationary	growth	phases	
(22).		Intestinal	damage	from	the	toxin	occurs	only	when	there	is	direct	contact	
of	the	vegetative	cells	with	the	enterocytes	(4).	
Toxigenic	strains	contain	a	pathogenicity	locus	(PaLoc)	that	carries	the	
genes	necessary	for	production	and	regulation	of	toxin	A	and	B,	both	of	which	
have	been	associated	with	CDI	(1).		Toxin	A	(TcdA)	is	an	enterotoxin,	while	toxin	
B	(TcdB)	is	a	cytotoxin	(1).	Both	alter	the	function	of	GTPases	from	the	Ras	
superfamily,	which	leads	to	cell	shrinking,	disruption	of	cell‐signaling	pathways	
and	cytoskeleton	integrity,	and	eventually	cell	death	(1,	4).		The	tcdC	gene	in	the	
PaLoc	encodes	an	anti‐sigma	factor	that	regulates	TcdA	and	TcdB.		Some	C.	
difficile	ribotype	027	strains	have	a	missense	mutation	in	the	tcdC	gene,	which	is	
believed	to	enhance	the	strain’s	toxin	production	(5).		
	Intoxication	leads	to	fluid	accumulation	and	increased	vascular	
permeability	(4).		Toxins	also	stimulate	the	release	of	tumor	necrosis	factor	and	
cytokines	that	induce	an	significant	inflammation	response	(1).		Tissue	damage	is	
characterized	by	epithelial	cell	loss	and	significant	neutrophil	infiltration	that	
contribute	to	local	and	systemic	manifestations	of	CDI	(4).		
Some	C.	difficile	strains,	including	ribotype	027,	also	produce	a	binary	
toxin,	also	known	as	C.	difficile	transferase	(CDT)	(5,	34).	CDT	is	found	in	
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approximately	6‐12.5%	of	C.	difficile	strains	(1).		CDT	is	an	ADP‐ribosylating	
toxin	that	affects	the	cell’s	cytoskeleton,	leading	to	fluid	loss,	rounding	of	the	cell,	
and	cell	death	(1).		CDT	also	forms	long	protrusions	that	improve	adhesion	of	C.	
difficile	vegetative	cells	to	the	epithelium	(34).		The	presence	of	CDT	is	associated	
with	a	greater	virulence	and	mortality	(5).		
	
2.4.0.	Clinical	Manifestations	
	
2.4.1.	Asymptomatic	carriers	
	
Approximately	5%	of	healthy	adults	and	30‐70%	of	healthy	infants	carry	
C.	difficile	asymptomatically	(3).	Protection	of	adults	with	asymptomatic	
colonization	may	stem	from	the	host’s	antibody	response	against	toxin	A	(7).	In	
the	case	of	healthy	infants,	the	protection	may	be	related	to	the	absence	of	toxin	
receptors	or	poorly	developed	cell‐signaling	pathways	in	the	gut	mucosa	(50).	
Although	there	is	no	formal	definition,	at	least	one	author	suggests	that	
asymptomatic	colonization	with	C.	difficile	occurs	when	the	bacteria	is	present	in	
stool	of	an	individual	without	CDI	symptoms	over	a	period	of	7	days	(51).	
Asymptomatic	carriage	is	assumed	to	be	more	likely	among	those	in	
healthcare	than	community	settings.	An	estimated	10%	of	hospitalized	patients	
in	acute‐care	facilities	and	up	to	15%	of	patients	in	long‐term	care	facilities	
asymptomatically	carry	C.	difficile	at	admission	(52,	53).		Furthermore,	up	to	21%	
of	inpatients	may	become	colonized	during	their	hospitalization,	most	of	which	
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remain	asymptomatic.		This	group	is	suspected	to	play	an	important	role	in	
ongoing	healthcare	transmission	(3,	22).				
	
2.4.2.	Clostridium	difficile	infection	(CDI)		
	
The	Infectious	Diseases	Society	of	America	and	Society	for	Healthcare	of	
Epidemiology	of	America	(IDSA/SHEA)	defines	CDI	as	the	passage	of	three	or	
more	unformed	stools	in	24	hours	combined	with	a	positive	stool	sample	for	
toxigenic	C.	difficile,	or	its	toxins,	and/or	histopathological	findings	associated	
with	pseudomembranous	colitis	(51).		However,	CDI	can	present	with	a	broad	
spectrum	of	clinical	manifestations	ranging	from	mild	diarrhea	to	more	severe	
disease.		Severe	manifestations	include	toxic	megacolon,	pseudomembranous	
colitis,	sepsis,	and	death	(13).		Up	to	25%	of	antibiotic‐associated	diarrheal	cases	
are	attributed	to	C.	difficile	(12).		
	
2.4.3.	CDI	severity	
	
Although	it	seems	biologically	plausible,	the	question	remains	as	to	
whether	toxin	levels	are	directly	correlated	with	severity	of	symptoms	and	
disease.	In	2006,	Akerlund	et	al.	reported	a	positive	correlation	among	164	
patients	between	diarrhea	severity	and	fecal	toxin	levels	detected	by	Toxin	
Enzyme	Immunoassay	(EIA)	(54).		Moreover,	Planche	et	al.	(2013)	reported	a	
significantly	higher	mortality	among	435	patients	with	detectable	fecal	levels	of	
toxin	using	Cell	Cytotoxicity	Assay	(CCTA)	versus	patients	only	positive	through	
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Cytotoxigenic	Culture	(CC)	(n=207)	or	CDI	negative	patients	(n=5880)	(55).		By	
contrast,	Anikst	et	al.	(2015)	observed	no	significant	difference	in	mean	fecal	
toxin	concentrations	between	patients	with	(n=59)	or	without	(n=59)	clinically	
significant	diarrhea	(three	or	more	episodes	in	24	hours)	with	toxin	detected	
using	a	quantitative	Toxin	A	and	B	ELISA	and	a	qualitative	toxin	EIA	(56).		
Similarly,	Rao	et	al.	(2015)	recently	reported	that	among	1144	CDI	cases	(37.2%	
EIA	Toxin	positive)	detectable	toxin	was	not	predictive	of	CDI	severity	and	
mortality	(57).		Differences	in	observed	results	may	be	due	to	differences	on	
tests’	sensitivities,	study	power,	CDI	prevalence	in	the	study	population,	and	
outcome	definitions.			
	 There	is	also	limited	evidence	associating	spore	levels	with	CDI	severity.		
Carlson	et	al.	(2013)	compared	in	vitro	sporulation	patterns	from	106	C.	difficile	
clinical	isolates.		Although	the	authors	were	unable	to	detect	a	significant	
association	between	spore	levels	and	ribotype,	they	observed	significantly	higher	
sporulation	among	isolates	associated	with	severe	CDI	(n=	34)	versus	those	from	
non‐severe	cases	(n=	72)	(58).		Furthermore,	Deakin	et	al.	demonstrated	that	
spo0A	gene	is	essential	in	CDI	persistent	disease,	in	addition	to	C.	difficile	
transmission	(59).			
	 Other	studies	have	focused	on	the	relationship	between	C.	difficile	burden	
in	the	gut	and	CDI	severity.		If	CDI	severity	is	truly	correlated	with	gut	levels	of	
toxin,	there	should	also	be	an	observable	correlation	between	levels	of	C.	difficile	
vegetative	cells	in	the	gut	and	disease	severity,	assuming	all	vegetative	cells	are	
producing	toxins	equally	and	simultaneously.		To	quantify	the	number	of	
vegetative	cells	in	the	gut,	several	studies	have	used	a	Real‐Time	PCR	(RT‐PCR)	
assay	that	detects	the	gene	of	Toxin	B	(tcdB)(Cepheid	Xpert).		Baker	et	al.	(2013)	
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observed	that	the	PCR	cycle	threshold	(CT)	values	from	EIA	Toxin	positive	
patients	(n=42)	were	usually	strong	(<30);	however,	EIA	negative	patients	
(n=87)	tended	to	have	a	wide	range	of	CT	values	(60).		These	results	suggest	that	
a	high	burden	of	C.	difficile	vegetative	cells	correlates	with	detectable	levels	of	
toxin	in	stool;	however,	the	converse	was	not	observed	for	EIA	negative	patients.		
Furthermore,	Rao	et	al.	(2015)	reported	no	association	between	CT	values	and	
CDI	severity	and	mortality	among	718	PCR	positive	patients	(57).		Anisk	et	al.	
(2015)	were	also	unable	to	find	a	significant	difference	in	CT	values	between	
patients	with	or	without	significant	diarrhea	(p=0.25)	(56).		By	contrast,	
Reigadas	(2016)	et	al.	recently	reported	that	a	low	PCR	CT	value	appeared	to	be	
strong	predictor	of	poor	CDI	outcome,	defined	as	recurrent	CDI,	treatment	failure	
or	advancement	to	severe	complications.		The	authors	proposed	a	cut‐off	of	less	
than	23.5	toxin	B	CT	value	for	prediction	of	poor	outcome	with	a	diagnostic	
accuracy	of	88.1%	(61).			
Studies	linking	specific	ribotypes	to	CDI	severity	have	also	presented	
conflicting	evidence.		Walk	et	al.	(2012)	performed	a	cross‐sectional	study	
comparing	310	CDI	cases	(11%	of	which	were	classified	as	severe	cases).		
Although	ribotype	027	and	078	were	found	to	be	good	predictors	of	severity,	this	
did	not	hold	after	adjusting	for	confounders	(62).		By	contrast,	Miller	et	al.	(2010)	
reported	a	strong	association	between	ribotype	027	and	CDI	severity.		Among	
1008	patients	from	the	Canadian	Nosocomial	Infection	Surveillance	Program,	
12.5%	of	all	patients	infected	with	a	NAP1	strain	(n=311)	developed	a	severe	
outcome	in	comparison	to	only	5.9%	of	patients	infected	with	another	type	(63).		
Similarly,	Walker	et	al.	(2013)	reported	that	C.	difficile	genotype	was	a	good	
predictor	of	CDI	severity.		This	study	observed	that	patients	with	ribotype	078	
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(Clade	5)	showed	a	25%	(16	of	63)	14‐day	mortality,	while	ribotype	027	(Clade	
2)	was	20%	(111	of	560),	both	significantly	higher	than	clade	1	with	only	12%	
(137	of	1168)	(64).		Rao	et	al.	(2015)	also	reported	an	association	between	
ribotype	027	and	CDI	severity/mortality	even	after	adjusting	for	age	(57).		
Similar	results	have	been	described	when	comparing	ribotype	027	with	other	
ribotypes	(015	or	106)	(65,	66).		These	differences	in	results	could	potentially	be	
explained	by	differences	in	study	populations,	timing	of	CDI	diagnosis,	circulating	
strain	types,	and	administered	treatment	(67).				
	
2.5.0.	Diagnosis	
	
	 Presence	of	watery	diarrhea,	fever,	leukocytes,	loss	of	appetite,	nausea,	
and	abdominal	pain	and	tenderness	are	the	most	common	symptoms	associated	
with	CDI	(68);	however,	as	they	are	not	specific	to	CDI,	laboratory	confirmation	is	
required.		To	minimize	risk	of	misdiagnosis	due	to	asymptomatic	carriage,	
accurate	C.	difficile	laboratory	diagnosis	depends	on	detecting	the	presence	or	
production	of	Toxin	A	and	Toxin	B	by	toxigenic	strains	(69).		To	further	minimize	
potential	for	misdiagnosis,	most	laboratories	only	test	soft	or	liquid	stools	for	CDI	
(17).				
	 IDSA/SHEA	recommends	a	two	or	three‐step	algorithm	for	CDI	diagnosis	
(69,	70).		This	algorithm	uses	glutamate	dehydrogenase	(GDH)	detection	as	a	
screening	test,	followed	by	or/and	in	conjunction	with	a	method	detecting	either	
toxigenic	C.	difficile	and/or	C.	difficile	toxins	as	a	confirmatory	test	(17).			
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GDH	is	a	cell	wall	antigen	found	in	both	toxigenic	and	non‐toxigenic	C.	
difficile	strains.		The	GDH	detection	test	cross‐reacts	with	other	intestinal	
microorganisms,	affecting	its	specificity,	but	it	has	a	high	sensitivity	(87‐90%)	
and	negative	predictive	value	(above	99%),	making	it	a	good	screening	test	in	
symptomatic	populations	(17,	69).		If	samples	are	positive	for	GDH,	several	
confirmatory	tests	could	follow;	however,	it	is	essential	to	understand	the	
differences	in	the	principle	and	target	of	each	specific	test,	as	they	have	the	
potential	to	impact	clinical	and	infection	control	decisions.			
SHEA/IDSA	recommends	the	use	of	cytotoxigenic	culture	(CC)	or	cell	
cytotoxicity	assay	(CCTA)	as	confirmatory	tests	(70).		CCTA	is	based	on	the	
neutralization	of	the	toxins’	cytopathic	effect	in	cell	culture	in	the	presence	of	
antitoxin	antibodies	(71).		By	contrast,	CC	relies	on	the	culture	of	C.	difficile	
spores	in	stool.		After	culture,	detection	of	toxins	either	by	CCTA	or	a	toxin	
enzyme	immunoassay	(EIA)	is	necessary	to	rule	out	non‐toxigenic	strains	(72).		
CCTA	and	CC	are	considered	reference	laboratory	methods	for	CDI	detection	as	
they	are	very	sensitive	and	specific;	however,	they	are	labor‐intensive,	and	time‐
consuming	with	a	slow	turn	around	(69).		In	addition,	they	require	special	
expertise	and	technology	not	always	available	in	clinical	settings.			
An	alternative	is	to	use	EIA	to	detect	the	presence	of	C.	difficile	toxins.	
Toxin	A/B	EIA	has	moderate	sensitivity	(25‐86%)	and	specificity	(75‐100%)	
compared	to	reference	methods.		However,	due	to	its	moderate	sensitivity,	EIA	
Toxin	tests	are	recommended	only	as	part	of	a	two	or	three	step	algorithm	(71,	
73).		Other	available	confirmatory	tests	are	nucleic	acid	amplification	tests	
(NAAT),	including	real‐time	PCR,	helicase‐dependent	amplification,	and	loop‐
mediated	isothermal	amplification,	all	of	which	have	a	greater	sensitivity	(73‐
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100%)	than	EIAs	compared	to	CC,	and	shorter	turnaround	time	in	comparison	to	
CCTA	(17).		Using	PCR	as	the	third	or	second	step	in	the	lab	algorithm	is	
recommended	(17,	73).		
At	the	University	of	Michigan	Health	System	and	the	St.	Joseph	Mercy	
Hospital	in	Ann	Arbor,	a	two‐step‐algorithm	is	usually	used	for	clinical	diagnosis,	
composed	of	a	GDH/Toxin	EIA	as	an	initial	test	followed	by	PCR.		This	algorithm	
is	estimated	to	have	100%	(95%CI	78‐100%)	sensitivity	and	97%	specificity	
(95%CI	93‐99%)	(17).			
Nonetheless,	NAATs	only	detect	C.	difficile	toxin	genes	(tcdA,	tcdB,	and/	or	
tcdC)	and	thus	cannot	identify	the	functionality	or	production	of	that	toxin	(69).		
Because	of	this,	even	though	PCR	improves	both	the	specificity	and	sensitivity	of	
the	laboratory	diagnosis,	its	introduction	has	raised	several	questions	regarding	
its	clinical	applicability	because	PCR	tests	cannot	distinguish	between	
colonization	and	disease	states	(17,	74).		Knowing	that	an	estimated	10%	of	
hospitalized	patients	are	colonized	with	C.	difficile	(52,	53)	and	that	most	cases	of	
nosocomial	diarrhea	are	not	associated	with	CDI	(75),	it	is	likely	that	some	
patients	with	diarrhea	are	simultaneously	also	C.	difficile		carriers	and	will	be	
mistakenly	diagnosed	as	CDI	positive	patients	by	PCR	(76).		When	compared	to	
CCTA,	50‐80%	more	positives	are	detected	using	NAATs	(71).	In	these	cases,	PCR	
may	result	in	overdiagnosis	and	overtreatment	(17,	76).		
Some	studies	report	no	significant	difference	between	clinical	and	
laboratory	characteristics	between	CD	toxin	positive	or	toxin	negative/PCR	
positive	patients(57,	77);	however,	among	53	toxin	negative/PCR	positive	
patients	in	comparison	to	24	toxin	positive	patients,	Baker	et	al.	(2013)	found	a	
significantly	lower	14	days	all‐cause	mortality	and	a	smaller	proportion	with	
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prolonged	diarrhea	(>5	days)	(60).		In	this	same	study,	97%	of	toxin	
negative/PCR	positive	patients	resolved	their	diarrhea	within	14	days	without	
receiving	CDI	treatment	(60).		Similarly,	Polage	et	al.	(2015)	reported	that	toxin	
negative/PCR	positive	patients	(n=162)	had	comparable	outcomes	with	CDI	
negative	patients	(n=	1123)	(78).	
	
2.6.0.	CDI	Recurrence	
	
The	current	recommended	treatment	for	CDI	is	oral	metronidazole	or	
vancomycin;	however,	CDI	recurs	in	5‐35%	of	patients	following	appropriate	
treatment	(5,	58,	79).		A	recurrent	case	is	defined	as	an	episode	of	CDI	that	occurs	
8	weeks	or	less	after	a	previous	CDI	case	has	been	resolved	(19).	First‐time	
recurrences	are	more	common	among	hospital‐associated	cases	(21%)	than	
among	community‐associated	ones	(14%)	(9).		In	addition,	approximately	12%	
of	CDI	patients	have	two	recurrences,	while	6%	have	more	than	two	(67).		
Clinically,	it	is	not	possible	to	determine	if	a	recurrent	case	is	a	relapse	of	
the	same	infection,	a	new	infection	with	a	different	strain,	or	a	new	infection	with	
the	same	strain	(80).		However,	after	strain	fingerprinting	using	both	serotyping	
and	PCR‐ribotyping,	Barbut	et	al.	(2000)	reported	that	45	out	of	93	(48.4%)	
recurrences	in	his	study	population	were	due	to	a	new	infection,	reporting	42	
days	as	a	mean	of	time	between	the	two	cases	(81).		By	contrast,	Figueroa	et	al.	
(2012)	using	restriction	endonuclease	analysis	(REA)	concluded	that	relapses	
were	more	common	than	reinfections	in	both	early	(1‐14	days	after	treatment)	
and	late		(15‐31	days)	recurrences	(80),	where	only	13.3%	or	23.3%	recurrences	
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respectively	were	due	to	new	strains.		Thus,	relapses	are	considered	to	occur	on	
average	14.5	days	after	the	initial	CDI	case,	while	a	reinfection	occurs	on	average	
after	42.5	days	(82).			
	Risk	factors	associated	with	CDI	development	‐‐	antibiotic	resistance,	
weakened	immune	response,	and	disturbed	gut	microbiota	(5,	82,	83)	‐‐	are	also	
associated	with	CDI	recurrence.	In	addition,	initial	CDI	infection	with	ribotype	
027	is	considered	as	a	risk	factor	of	recurrence	(84).		In	North	America,	C.	difficile	
strains	from	group	REA	B1,	which	includes	ribotype	027	are	responsible	for	47%	
of	CDI	recurrences	(80).		
	 Tapered‐pulsed	vancomycin	treatment	is	recommended	for	treating	CDI	
recurrence,	particularly	following	a	second	recurrence	(85).	This	usually	consists	
of	a	regimen	of	lower	doses	of	vancomycin	for	7‐10	days,	followed	by	several	
extra	doses	every	48	or	72	hours	for	up	to	8	weeks	(85).		This	regimen	is	
expected	to	reduce	antibiotic	levels	in	the	gut	just	enough	for	the	remaining	
spores	to	germinate	into	vegetative	cells,	a	state	when	vancomycin	is	expected	to	
be	effective.		Furthermore,	a	tapered/pulsed	regimen	is	assumed	to	provide	a	
chance	for	the	healthy	gut	microbiota	to	recover	while	C.	difficile	is	suppressed	
(85‐87).		For	further	recurrences,	other	treatments	have	been	suggested	such	as	
Fecal	Microbiota	Transplant,	probiotics,	immunotherapy,	or	newer	drugs	such	as	
fidaxomicin	(82).	
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2.7.0.	Toxin‐spore	correlation	
	
Finally,	another	important	issue	that	may	potentially	shed	some	light	into	
the	pathogenicity	and	transmission	patterns	of	C.	difficile	is	the	association	
between	its	toxin	and	spore	production.		Toxin	and	spore	production	requires	an	
important	amount	of	energy	from	the	bacteria;	therefore,	it	is	biologically	
plausible	that	the	bacteria	trade	offs	one	process	for	the	other	during	its	life	
cycle.		Evidence	of	this	trade‐off	(or	its	absence)	would	provide	valuable	insights	
to	inform	CDI	management,	treatment,	and	control	and	prevention	for	both	
symptomatic	and	asymptomatic	carriers.		
Positive	and	negative	correlations	have	been	reported	between	spore	and	
toxin	production.		Underwood,	et	al.	(2009)	demonstrated	that	inactivation	of	a	
known	spore	regulator,	Spo0A,	negatively	affected	both	spore	and	toxin	
production	in	the	C.	difficile	630	strain,	but	this	result	was	not	confirmed	by	
Mackin	et	al.	(2013)	using	the	same	strain	(88,	89).		However,	Mackin	et	al.	
(2013)	also	showed	that	SpoA	negatively	regulates	toxin	A	and	B	levels	in	
ribotype	027	(89).		Akerlund	et	al.	(2006)	compared	toxin	yield	and	spore	levels	
among	13	clinical	isolates	in	vitro	and	observed	an	inverse	correlation	(54).		By	
contrast,	spores	and	toxins	were	produced	simultaneously	24	hours	after	
infection	in	a	mouse	model	(N=30),	suggesting	a	positive	correlation	between	
fecal	toxin	and	spores	levels	(41).			
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2.8.0.	Public	Health	Significance		
	
If	a	correlation	between	spores	and	toxins	is	identified	in	vivo,	toxin	levels,	
which	may	be	measured	using	current	laboratory	techniques,	could	be	used	as	“a	
proxy”	of	fecal	spore	levels.		Doing	so	would	allow	us	to	identify	patients	who	are	
likely	to	shed	a	large	number	of	spores	during	their	hospital	stay	and	who	should	
be	given	further	attention	from	an	infection	control	perspective.		Similarly,	the	
correlation	would	provide	further	support	to	a	re‐analysis	of	the	need	to	identify	
C.difficile	carriers	in	healthcare	settings	and	determine	whether	they	should	be	
under	isolation	precautions	while	hospitalized.		
Moreover,	identifying	a	positive	in	vivo	correlation	between	spores	and	
toxin	levels	will	provide	further	evidence	to	determine	the	clinical	applicability	of	
molecular	tests	for	CDI	diagnosis,	treatment,	and	infection	control.	It	is	essential	
to	understand	the	role	played	by	both	Toxin	positive	and	Toxin	negative	PCR	
positive	individuals	in	CDI	transmission,	in	order	to	improve	CDI	control	and	
prevention	guidelines	not	only	in	acute‐care	settings	but	also	in	outpatient	
facilities	and	community	settings.	
Finally,	increasing	our	knowledge	about	the	impact	of	host	factors	on	
spore	and	toxin	levels	will	provide	us	with	more	clear	guidelines	to	tailor	
infection	control	practices	toward	reducing	the	spread	of	C.difficile	within	
healthcare	settings.		Particularly,	improved	understanding	of	the	effect	of	
Candida	spp.	on	C.difficile	spore	and	toxin	levels	will	inform	the	treatment	and	
management	of	both	CDI	and	Candidiasis	patients	to	avoid	further	medical	
complications.
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CHAPTER	III	
Clostridium	difficile	shows	no	trade‐off	between	toxin	and	spore	production	
within	its	human	host	
	
3.0.0.	Abstract		
	
Clostridium	difficile	is	the	most	commonly	reported	microorganism	associated	
with	nosocomial	infections	in	the	US	Healthcare	system.		Toxin	and	spore	levels	
are	associated	with	severity	of	C.	difficile	infection	(CDI)	suggesting	that	toxin	and	
spore	production	may	be	positively	correlated.		While	both	positive	and	negative	
correlations	have	been	reported	in	the	literature,	no	studies	have	described	the	
correlation	within	an	infected	human	host.		Our	study	aimed	to	fill	this	gap	by	
directly	measuring	C.	difficile	spore	and	toxin	levels	in	CDI	positive	stool	samples.		
We	also	assessed	whether	overgrowth	of	Candida	albicans	modified	this	
association,	as	C.	albicans	has	been	suggested	as	both	a	risk	and	a	protective	
factor	for	C.	difficile.		We	measured	toxin,	spore,	and	C.	albicans	levels	among	200	
successively	collected	stool	samples	testing	positive	for	CDI,	and	PCR	ribotyped	
the	recovered	C.	difficile	isolates.		Growth	of	≥5	logs	of	C.	albicans	CFU/g	of	stool	
was	defined	as	overgrowth.		C.	difficile	toxin	and	spore	levels	were	positively	
associated	(p<0.001);	this	association	did	not	vary	by	C.	albicans		overgrowth.		
However,	ribotypes	027/078	were	significantly	associated	with	high	levels	of	
toxin	and	of	spores	and	C.	albicans	overgrowth.		Although	on	average	spore	levels	
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were	higher	in	toxin	positive	samples	than	in	toxin	negative/PCR	positive	
samples,	spores	were	found	in	almost	all	toxin	negative	samples.		The	ubiquity	of	
spore	production	emphasizes	the	importance	of	strictly	following	already	
establish	CDI	control	and	prevention	measures	in	healthcare	settings.		
Furthermore,	our	study	highlights	the	importance	of	considering	the	
asymptomatic	state	when	implementing	CDI	diagnosis,	treatment,	and	control	
and	prevention	measures.	
	
3.1.0.	Introduction		
	
Clostridium	difficile	infection	(CDI)	is	one	of	the	most	important	
healthcare‐associated	infections	(HAIs).		In	the	United	States	(US),	CDI	accounts	
for	12%	of	HAIs,	leading	to	almost	500,000	infections	and	approximately	29,000	
deaths	per	year	(1‐3).		The	associated	costs	are	significant:	CDI	costs	an	
estimated	4.8	billion	dollars	per	year	among	US	acute	care	facilities	(4).		
	CDI	is	defined	by	the	presence	of	diarrhea	and	other	symptoms,	and	one	
of	the	following:	a	stool	test	positive	for	C.	difficile	toxins	or	C.	difficile	toxin	genes	
or	the	presence	of	pseudomembranous	colitis	(5).		Symptomatic	CDI	is	attributed	
to	toxin	production.		Therefore,	laboratory	diagnosis	may	follow	a	multi‐step	
algorithm	that	includes	an	initial	test	for	a	C.	difficile	highly	conserved	cell	wall‐
associated	enzyme,	glutamate	dehydrogenase	(GDH),	followed	by	a	test	for	toxin	
(6).		If	negative	for	detectable	toxin	but	positive	for	GDH,	the	sample	is	tested	for	
the	presence	of	toxin	genes	using	a	PCR	assay	(6).		This	multi‐step	algorithm	
assumes	that	the	presence	of	toxin	genes	is	indicative	of	disease	–	even	in	the	
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absence	of	detectable	toxin.		However,	diarrheal	symptoms	can	be	caused	by	
many	different	pathogens,	and	C.	difficile	is	found	among	an	estimated	5%	of	the	
general	population	(7)	and	8%	of	the	hospitalized	population	without	symptoms	
(8).		
In	addition,	there	are	many	different	C.	difficile	ribotypes.		Hypervirulent	
ribotypes	reportedly	produce	higher	levels	of	toxin	and	spores.		Warny	et	al.	
(2005)	reported	ribotype	027	(Toxinotype	III)	(n=15)	produced	an	average	of	16	
to	23	times	more	toxin	in	vitro	than	25	C.	difficile	isolates	from	Toxinotype	0	(9).		
By	contrast,	Merrigan	et	al.	(2010)	reported	4	hypervirulent	strains	(ribotype	
027)	did	not	produce	significantly	greater	amounts	of	toxins	than	4	non‐
hypervirulent	strains	(10).		However,	this	same	study	observed	a	significant	
difference	in	spore	production	among	the	hypervirulent	strains	(10).				
Severity	of	CDI	symptoms	is	expected	to	increase	with	toxin	levels	(11),	as	
CDI	is	considered	a	toxin‐mediated	intestinal	disease.		Whether	symptom	
severity	increases	with	spore	levels	is	less	certain.		Carlson	et	al.	(2013)	reported	
that	cultured	isolates	from	CDI	severe	cases	(n=34)	produced	more	spores	after	
24	hours	than	isolates	from	non‐severe	CDI	cases	(n=72)	(12).		Spores	germinate	
into	vegetative	cells,	so	if	there	are	more	spores	there	are	probably	more	
vegetative	cells	producing	toxin	‐‐	resulting	in	more	severe	disease	(12).		For	the	
latter	to	be	true,	toxin	and	spore	production	must	be	directly	correlated.		
	Underwood	et	al.	(2009)	demonstrated	that	inactivation	of	the	spore	
regulator,	Spo0A,	negatively	affected	both	spore	and	toxin	production	in	the	C.	
difficile	630	strain,	but	this	result	was	not	confirmed	by	Mackin	et	al.	(2013)	
using	the	same	strain	but	different	methods	(13,	14).		However,	in	the	same	
study	Mackin	and	colleagues	showed	that	SpoA	negatively	regulates	toxin	A	and	
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B	levels	in	ribotype	027	(14).		Akerlund	et	al.	(2006)	compared	toxin	yield	and	
spore	levels	among	13	clinical	isolates	in	vitro	and	observed	an	inverse	
correlation	(11).		By	contrast,	spores	and	toxins	were	produced	simultaneously	
24	hours	after	infection	in	a	mice	model	(N=30),	suggesting	a	positive	correlation	
between	fecal	toxin	and	spores	levels	(15).	Thus,	the	correlation	between	toxin	
and	spore	levels	in	humans	remains	to	be	confirmed.		The	magnitude	and	
direction	of	this	correlation	may	have	significant	implications	for	infection	
prevention	and	control.		
Although	toxin	production	is	essential	for	pathogenicity,	it	is	not	
sufficient.		Toxin	can	be	detected	in	the	absence	of	symptoms,	suggesting	that	
other	factors	modify	the	effect	of	the	toxin	on	the	host	(16).		One	factor	we	
hypothesize	to	potentially	mediate	the	effect	of	toxin	is	the	presence	of	Candida	
spp.	in	the	gut	microbiota.		Estimated	prevalence	of	Candida	spp.	in	the	gut	
ranges	from	16%	to	83%	among	CDI	patients	(17‐19)	and	23‐76%	among	
healthy	individuals	(20)	(but	only	10%	specifically	for	C.	albicans	(21)).	Although	
some	studies	have	reported	a	positive	or	a	negative	association	between	CDI	and	
Candida	spp.	(18,	19),	whether	if	the	presence	of	Candida	spp.	is	associated	with	
C.	difficile	spore	and	toxin	production	has	not	been	investigated.		
Our	study	aimed	to	fill	gaps	in	our	understanding	of	the	in	vivo	correlation	
of	C.	difficile	spore	and	toxin	levels	and	their	association	with	the	overgrowth	of	
C.	albicans	by	directly	testing	clinical	samples.		
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3.2.0	Methods	
	
3.2.1.	Sample	collection	
	
	We	collected	200	successive	CDI	positive	stool	samples	from	the	
microbiology	laboratory	at	Saint	Joseph	Mercy	Hospital	(SJMH)	in	Ann	Arbor,	
Michigan	(MI)‐	a	reference	laboratory	for	several	hospitals,	outpatient	healthcare	
centers,	and	urgent	care	facilities	within	the	Saint	Joseph	Mercy	Health	System.		
The	Institutional	Review	Boards	at	SJMH	and	the	University	of	Michigan	(IRB	
Health	Sciences	and	Behavioral	Sciences)	approved	our	study	protocol.		
We	included	all	samples	submitted	for	CDI	testing	between	February	1st	
and	July	20th,	2015	that	were	determined	to	be	positive	using	the	SJMH	
laboratory	algorithm	and	had	sufficient	volume	left	for	our	testing	protocol.		The	
SJMH	laboratory	algorithm	includes	an	initial	GDH/Toxins	AB	screening	using	
C.DIFF	QUIK	CHEK	COMPLETE®	(Alere,	Waltham,	MA./Techlab,	Blacksburg,	VA.).		
In	case	of	indeterminate	results,	samples	are	tested	using	a	tcdB	PCR	assay	
(Cepheid	Gene	Xpert®,	Sunnyvale,	CA.)	for	presence	of	the	toxin	genes	(Figure	
3.1).		We	recorded	the	age,	gender,	and	location	code	(inpatient	vs.	outpatient)	of	
the	individual	providing	the	sample,	and	qualitatively	assessed	the	physical	
consistency	of	the	study	stool	samples.		
Samples	were	classified	as	1)	formed/semi‐formed,	2)	soft	and	unformed,	
3)	liquid,	and	4)	mucoid.		As	diarrheic	samples	were	the	focus	of	our	study,	we	
considered	all	hard	or	soft	samples	that	retained	their	shape	in	their	collection	
cup	to	be	formed	or	semi‐formed.		Stools	that	were	loose	and	took	the	shape	of	
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the	collection	cup	were	identified	as	soft	and	unformed,	while	samples	that	could	
be	pipetted	and	resembled	the	consistency	of	water	were	defined	as	liquid.		Soft	
or	liquid	samples	that	contained	significant	amount	of	mucous	were	considered	
mucoid	(Modified	from	(22)).	
	
3.2.2.	Determination	of	toxin	levels	
	
Following	determination	of	positivity	by	the	SJMH	laboratory,	we	
measured	C.	difficile	toxin	AB	levels	using	the	C.	DIFFICILE	TOX	A/B	II™	
Immunoassay	(Techlab,	Blacksburg,	VA).		We	quantitated	the	color	intensity	of	
the	reaction	by	measuring	the	optical	density	at	450	nm	using	an	ELISA	plate	
reader	(PerkinElmer,	2030	Multilabel	Reader,	Waltham,	MA.)	according	to	the	
kit’s	manufacturer	instructions	(23).		Due	to	the	known	variability	of	this	assay,	
we	normalized	each	sample	value	by	subtracting	its	corresponding	negative	
control	and	dividing	this	value	by	its	positive	control,	also	corrected	by	
subtracting	its	negative	control	value.		Therefore,	we	report	the	ratio	of	toxin	
levels	in	each	sample	relative	to	that	in	the	positive	control.		In	addition,	due	to	
the	high	intra‐assay	coefficient	of	variation	(10%	across	fecal	specimens	(23)),	
we	categorized	our	toxin	levels	based	on	quantiles.	
	
3.2.3.	Determination	of	spore	levels	
	
	Following	a	heat	treatment	(65oC	for	20	minutes),	spore	levels	were	
quantified	by	culturing	serial	dilutions	of	the	fecal	specimen	on	Cycloserine	
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Cefoxitin	Fructose	Agar	with	Horse	Blood	and	Taurocholate	(Anaerobe	Systems,	
Morgan	Hill,	CA.)	for	24	hours	at	37oC	under	anaerobic	conditions.		Spore	levels	
were	reported	as	colony	forming	units	(CFU)	per	gram	of	feces.	
	
3.2.4.	Detection	of	Candida	albicans	
	
		 DNA	was	extracted	in	duplicate	from	200‐250uL	of	stool	using	the	
PowerMag®	Soil	Isolation	Kit	(Mo	Bio,	Carlsbad,	CA)	optimized	for	epMotion®	
(Mo	Bio,	Carlsbad,	CA).		C.	albicans	levels	were	quantified	in	triplicate	for	each	
extraction	using	RT‐PCR	(BioRad,	CFX96	Realtime	System,	Hercules,	CA)	with	
conditions	and	primers	previously	described	(24).		Because	stool	is	not	a	
microbiologically	and	chemically	homogeneous	sample,	we	analyzed	6	replicates	
of	each	sample:	if	at	least	2	out	of	the	6	replicates	were	positive	the	sample	was	
considered	positive	and	an	average	level	of	C.	albicans	was	calculated	from	the	
detected	estimates.		C.	albicans	overgrowth	was	defined	as	the	growth	of	≥5	logs	
of	CFU/g	of	stool	as	described	by	Raponi	et	al.	(2014)	(25).	
	
3.2.5.	Ribotyping	of	C.difficile	isolates	
	
A	fluorescent	PCR	ribotyping	technique	using	capillary	gel	electrophoresis	
was	performed	to	ribotype	the	C.	difficile	isolates	recovered	from	our	study	
samples	as	previously	described	(26).				
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3.2.6.		Determination	of	dry	weight	of	samples	
	
Samples	from	severe	cases	are	expected	to	be	more	diarrheic,	which	may	
dilute	spore	and	toxin	levels	resulting	in	an	underestimation	of	toxin	and	spore	
production	especially	in	more	severe	cases.		To	determine	if	this	bias	occurred,	
we	desiccated	the	159	samples	with	sufficient	material	remaining	in	a	vacuum	
concentrator	(eppendorf	Vacufuge™	AG	22331,	Hamburg,	Germany)	at	60oC	and	
1400	revolutions	per	minute	for	3	hours.		The	wet	gram	weight	of	each	stool	
sample	used	for	toxin	and	spore	quantification	was	adjusted	to	quantity	per	dry	
gram	weight.		For	the	remaining	41	specimens	without	sufficient	sample,	we	
imputed	water	content,	dry	spore,	and	dry	toxin	levels,	using	SAS	multiple	
imputation.		Water	content	results	also	were	used	to	validate	our	qualitative	
classification	of	stool	consistency.	
	
3.2.7.		Statistical	analysis	
	
To	test	if	the	distribution	of	spores	was	significantly	different	across	toxin	
categories	for	both	wet	and	dry	samples	we	used	ANOVA,	linear	regression,	and	
Test	of	trend.		Kruskal	Wallis	test	or	Mantel‐Haenszel	was	used	to	compare	toxin	
levels	between	groups	of	different	age,	gender,	location,	stool	consistency,	C.	
difficile	ribotype	and	Candida	growth.		T‐test	or	ANOVA	was	used	to	compare	log‐
transformed	spore	levels	between	the	different	groups	including	laboratory	
diagnosis	at	SJMH	(toxin	positive	or	toxin	negative/PCR	positive)	and	water	
content.		Finally,	univariate	and	multivariate	ordered	logistic	regression	and	
linear	regression	were	used	to	estimate	the	measures	of	association	linked	to	
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toxin	or	spore	(log‐transformed)	levels	with/without	adjustments	for	
confounders.		SAS	9.4	(Cary,	NC.)	and	STATA	14	(College	Station,	TX.)	were	used	
to	perform	all	analysis	and	graphics.	
	
3.3.0	Results		
	
Of	the	200	stool	samples,	90	were	from	inpatients	and	110	from	
outpatients	(including	ER	patients).		Most	samples	were	from	females	(60.5%)	
and	half	(50.5%)	from	individuals	aged	65	or	older.		Stool	sample	consistencies	
were	primarily	soft	(40.5%),	liquid	(32.0%),	mucoid	(in	addition	to	liquid	or	soft)	
(19.5%),	or	semi‐formed/formed	(8.0%).			
There	were	a	total	of	37	different	ribotypes	among	our	collected	isolates	
(Table	3.1,	Appendix	3.1).	The	most	common	ribotypes	were	027	(19%)	and	014‐
020	(16%).		Ribotype	078‐126	occurred	in	5	samples;	this	and	ribotype	027	are	
considered	hypervirulent	(27,	28).		Therefore,	they	were	combined	for	further	
analysis.		The	median	toxin	level	after	normalization	was	0.01	(range	‐0.06	to	
3.94),	but	this	varied	by	ribotype	(Table	3.1).	The	median	number	of	spores	
detected	was	1.6	x104	CFU/g	(range	0	to	5.5x106),	and	also	varied	by	ribotype	
(Table	3.1).		
There	was	a	significantly	different	distribution	of	log‐transformed	spore	
levels	by	toxin	category	(p<0.001)	(Figure	3.2).		The	ANOVA	results	describing	
differences	between	spore	levels	by	toxin	categories	did	not	change	after	
correcting	for	dry	weights	(p<0.001).		Similarly,	estimates	obtained	from	a	linear	
regression	that	modeled	log‐transformed	spores	as	the	outcome	and	either	wet	
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toxin	levels	or	those	corrected	for	dry	weight	as	the	independent	variable	were	
not	statistically	significantly	different	(not	shown).		
We	observed	a	strong	positive	association	between	toxin	and	spore	
production	that	remained	after	controlling	for	age,	gender,	location,	stool	
consistency,	and	ribotype	(Linear	regression,	p<0.001).		Moreover,	a	strong	
positive	trend	was	observed	between	toxin	and	spores	levels	(Test	of	trend,	
p<0.001).		When	we	stratified	by	ribotype,	the	strong	positive	trend	remained.		
However,	when	the	analysis	was	restricted	to	014‐020	isolates,	the	observed	
increase	in	spore	production	with	toxin	level	was	not	statistically	significant	
(Test	of	trend,	p=0.10)	(Figure	3.2).			
Toxin	negative/PCR	positive	stool	samples	had	significantly	fewer	spores	
in	vivo	than	toxin	positive	samples		(T	test,	p<0.001)	(Figure	3.3).		When	
stratified	by	ribotype,	a	significant	difference	in	spore	level	was	still	observed	by	
diagnostic	test	for	ribotype	027/78	and	014‐020	(Figure	3.4).			
Toxin	levels	did	not	significantly	differ	by	age	(p=0.51)	or	gender	
(p=0.89).	Outpatients	were	1.70	(95%CI	1.00‐2.90)	times	more	likely	than	
inpatients	to	have	higher	toxin	levels;	however,	after	adjusting	for	age,	gender,	
stool	consistency,	and	ribotype	in	a	multivariate	ordered	logistic	regression	the	
association	was	no	longer	statistically	significant	(OR=1.61	(95%CI	0.88‐2.93)).		
Stool	samples	infected	with	ribotypes	027	or	078	compared	to	other	ribotypes	
(excluding	014‐020)	were	2.19	(95%	CI	0.99‐4.84)	times	more	likely	to	have	high	
levels	of	toxin.		This	association	remained	strong	after	adjusting	by	age,	gender,	
location,	and	stool	consistency	(OR=2.24	(95%	CI	0.99‐5.05)).		By	contrast,	those	
with	ribotype	014‐020	compared	to	other	ribotypes	(excluding	027	and	078)	had	
lower	toxin	levels	even	after	controlling	by	host	variables	(OR=0.11	(95%CI	0.01‐
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0.84).		Mucoid	samples	were	3.03	(95%	CI	1.47‐6.20)	times	more	likely	to	have	
higher	toxin	levels	than	soft	samples	(Appendix	3.2).	This	association	became	
stronger	after	controlling	for	gender,	age,	patient	location,	and	ribotype	(OR=3.9	
(95%	CI	1.69‐8.97).			
Spore	production	did	not	differ	by	gender	(p=0.38)	or	patient	location	
(p=0.64).		However,	patients	65	or	older	had	higher	average	levels	of	spores	than	
younger	patients	(p=0.07),	but	this	appears	to	be	attributed	to	differences	in	
ribotype	rather	than	location,	stool	consistency,	or	gender.		Mucoid	samples	also	
tended	to	have	higher	numbers	of	spores	than	samples	with	a	soft	consistency	
(p=0.07);	this	association	remained	after	adjusting	for	age,	gender,	location,	and	
ribotype	(p=0.05)	(Appendix	3.3).		Only	ribotype	014‐020	was	significantly	
associated	with	spore	levels	when	compared	to	other	ribotypes	(excluding	
027/078),	and	the	association	was	negative	(p=0.008)	and	remained	after	
adjustment	for	age,	gender,	location,	and	stool	consistency	(0.19	unit	change	of	
log‐transformed	spores	from	ribotype	014‐020	to	other	ribotypes,	p=0.008).			
	Liquid	stool	was	more	common	among	inpatients,	while	soft	stool	was	
more	common	among	outpatients	(p=0.02).		Although	water	content	was	
significantly	associated	with	stool	consistency,	(which	validates	our	qualitative	
assessment	(p<0.001,	Appendix	3.4)),	there	was	no	statistically	significant	
difference	between	water	content	and	patient	location	(p=0.64).		Stool	
consistency	was	distributed	differently	by	diagnostic	test	(p=0.04):	toxin	positive	
cases	were	more	likely	to	have	mucoid	stool	than	PCR	positive	patients	
(OR=5.21(95%CI=1.82‐14.94))	after	adjustment	for	host	variables	and	ribotype.		
Furthermore,	stool	samples	infected	with	ribotypes	027/078	were	4.55	(OR	
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95%CI	1.59‐13.04)	times	more	likely	to	be	mucoid	than	soft	after	controlling	for	
age,	gender,	and	location.	
C.	albicans	could	be	quantified	for	166	samples	(83%)	and	was	detected	in	
18%	of	samples.		No	significant	differences	by	gender,	age,	location,	or	stool	
consistency	were	identified	between	these	samples	and	those	that	could	not	be	
quantified	(due	to	lack	of	sample).		We	did	not	identify	any	significant	difference	
in	C.	albicans	levels	by	age	(p=0.80),	gender	(p=0.40),	stool	consistency	(p=0.80),	
or	spore	levels	(p=0.63).		We	observed	a	slight	difference	by	toxin	levels	
(p=0.10);	however	no	linear	trend	was	observed	(p=0.76)	between	both	
variables.		However,	outpatients	have	significantly	higher	average	levels	of	C.	
albicans	than	inpatients	(p=0.01).	This	relationship	remained	after	controlling	
for	age,	gender,	stool	consistency	and	C.	difficile	ribotype	in	a	multivariate	linear	
regression	model.		An	increase	of	3.97	CFU	log	of	C.	albicans	was	observed	
between	inpatient	and	outpatient	category	(p=0.05).	
High	levels	(“overgrowth”,	defined	as	5	or	more	logs	of	C.	albicans)	were	
detected	in	13%	(n=22).		C.	albicans	overgrowth	did	not	vary	by	age	(p=0.61)	or	
stool	consistency	(p=0.33).		Although	outpatients	were	2.4	times	more	likely	to	
have	C.	albicans	overgrowth	than	inpatients	(95%CI	1.0‐5.8),	this	association	was	
explained	by	C.	difficile	ribotype.		There	were	no	significant	differences	between	
the	distributions	of	toxin	(p=0.12)	or	spore	levels	(p=0.21)	between	patients	
with	C.	albicans	overgrowth	compared	to	those	without	it.		The	association	
between	spore	and	toxin	levels	was	not	affected	by	C.	albicans	overgrowth,	and	
was	still	significant	among	the	subset	of	samples	with	C.	albicans	overgrowth	
(ANOVA,	p<0.001)	and	among	the	subset	without	it	(ANOVA	p=0.04).		However,	
stool	samples	with	ribotypes	027/078	were	3.46	(OR	95%	CI	1.18‐10.17)	times	
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more	likely	than	other	ribotypes	(excluding	014‐020)	to	have	C.	albicans	
overgrowth,	and	this	association	remained	after	adjustment	by	host	variables	
(OR	4.32	(95%CI	1.38‐13.45).	
	
3.4.0.		Discussion		
	
We	observed	a	strong,	positive	trend	between	in	vivo	levels	of	C.	difficile	
toxin	and	spore	production	among	200	C.	difficile	positive	stool	samples	from	in‐	
and	outpatients.		This	trend	remained	even	after	stratifying	by	ribotype.		Toxin	
and	spore	levels	were	not	associated	with	C.	albicans	overgrowth,	although	
samples	with	ribotypes	027/078	were	more	likely	to	have	overgrowth.	Contrary	
to	a	previous	in	vitro	finding	(11),	our	results	do	not	support	a	trade‐off	between	
spore	and	toxin	production	within	the	human	CDI	host.		This	suggests	that	spore	
production	may	enhance	colonization	as	well	as	transmission.		While	results	of	a	
mouse	model	previously	suggested	a	positive	association	between	C.	difficile	
toxin	and	spore	levels	(15),	we	found	no	similar	reports	in	humans.			
Surprisingly,	we	observed	a	significant	overlap	in	the	distribution	of	spore	
levels	among	toxin	positive	and	toxin	negative/PCR	positive	samples	(Figure	
3.3),	which	persisted	after	stratifying	by	ribotype	(Figure	3.4	and	Figure	3.5).		
This	confirms	previous	reports	of	inter‐strain	variation	of	sporulation	and	
germination	patterns	across	ribotypes	(29‐31).		This	observed	overlap	raises	the	
question	of	whether	the	same	cell	population	produces	both	toxin	and	spores,	or	
if	the	cell	population	is	separated	into	toxin	and	spore	producers.		Saujet	et	al.	
(2011)	described	an	alternative	sigma	factor	SigH	in	C.	difficile	that	has	an	
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inverse	correlation	with	toxin	production	but	a	direct	one	with	spore	regulation	
(32).		This	supports	the	hypothesis	of	separate	populations	(33).		However,	in	a	
related	species,	Clostridium	perfringes,	spores	and	enterotoxin	(CPE)	are	released	
simultaneously	(34).		Further	studies	are	required	to	better	elucidate	how	spore	
and	toxin	production	might	be	linked	in	C.	difficile	and	to	identify	bacterial	and	
host	signals	regulating	their	productions	in	vivo.		
The	strong	toxin‐spore	association	suggests	a	reexamination	of	the	
interpretation	of	the	PCR	test.		Approximately	10%	of	hospitalized	patients	are	
colonized	with	C.	difficile;	thus	it	is	likely	that	some	patients	with	diarrhea	of	a	
different	etiology	also	carry	C.	difficile	(8,	35,	36).		In	these	cases,	lab	algorithms	
that	include	PCR	testing	may	result	in	overdiagnosis	and	overtreatment	(6,	35).	
The	increased	sensitivity	of	detection	and	corresponding	increase	in	treatment	
may	not	improve	prognosis.		Polage	et	al.	(2015)	reported	that	162	toxin	
negative/PCR	positive	patients	(among	whom	only	41%	received	CDI	treatment)	
had	outcomes	comparable	to	those	CDI	negative	by	either	test	(36).		Similarly,	
Baker	et	al.	(2013)	reported	that	the	symptoms	of	97%	of	toxin	negative/PCR	
positive	patients	(n=53)	resolved	after	14	days	without	CDI	treatment	(37).			
		In	order	to	reduce	overdiagnosis,	the	Society	for	Healthcare	
Epidemiology	of	America	and	the	Infectious	Diseases	Society	of	America	
(SHEA/IDSA)	guidelines	recommend	against	CDI	testing	of	formed	stools	or	test	
of	cure	(5),	yet	our	sample	contained	8%	(n=16)	formed/semi‐formed	stool	
samples.		Although	a	small	number	of	non‐diarrheic	samples	may	be	specifically	
requested	to	be	tested	by	the	physician,	this	higher	than	expected	percent	of	
formed/semi‐formed	stools	in	our	study	population	suggests	there	may	be	
underreporting‐‐particularly	of	semi‐formed	stools	(soft	but	still	formed)‐‐	in	
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clinical	settings.		Interestingly,	we	found	clinically	relevant	levels	of	toxin	and	
spore	production	in	these	samples.		These	findings	underscore	the	importance	of	
considering	the	full	clinical	picture	before	testing	for	C.	difficile,	as	once	it	is	found	
it	can	be	difficult	to	ignore.		Notably,	antibiotic	therapy	is	a	primary	risk	factor	for	
CDI	and	treating	asymptomatic	carriage	may	lead	to	CDI	and	transmission	to	
others	(38,	39).		However,	our	results	also	highlight	that	patients	with	no	or	
milder	symptoms	(formed/semi‐formed	stools)	still	may	merit	contact	
precautions	as	they	may	be	shedding	spores	at	significant	levels.			
Our	results	confirm	the	hypervirulence	previously	described	for	ribotypes	
027	and	078	(11,	27,	28).		These	ribotypes	were	strongly	associated	with	toxin	
positive	cases	and	higher	levels	of	fecal	toxin	and	spores	even	after	controlling	
for	age,	gender,	location,	and	stool	consistency.		However,	our	study	was	unable	
to	link	these	ribotypes	to	CDI	severity,	a	point	still	under	debate	(26,	40).			
The	prevalence	of	C.	albicans	in	our	collection	(18%)	is	similar	to	previous	
reports	among	CDI	patients.	In	a	double‐blinded,	randomized,	phase	III	clinical	
trial	in	multiple	hospitals	in	the	US	and	Canada,	Nerandzic	et	al.	(2012)	reported	
16%	Candida	spp.	positivity	among	301	CDI	patients	before	initiation	of	
treatment	(17).		Manian	et	al.	(2013)	reported	17%	Candida	spp.	overgrowth	
among	60	American	CDI	cases	(18).		In	addition,	only	one	previous	study	found	a	
positive	association	between	C.	albicans	and	CDI	(25),	however,	Manian	and	
colleagues	(18)	also	reported	the	contrary	association.		In	this	study,	we	did	not	
observe	an	association	between	C.	albicans	overgrowth	and	C.	difficile	toxin	and	
spore	fecal	levels.		As	far	as	we	know,	this	specific	association	has	not	been	
described	elsewhere.		Nerandzic	et	al.	(2012)	(17)	described	that	vancomycin	
treatment	can	favor	Candida	spp.	acquisition;	however,	our	samples	were	
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collected	based	on	the	hospital	protocol	before	CDI	treatment	was	given	for	the	
current	CDI	episode	(although	we	did	not	take	into	account	whether	this	was	a	
first	or	recurrent	episode).		Thus,	future	research	should	investigate	if	Candida	
spp.	affects	in	vivo	spore‐toxin	correlation	during	or	after	CDI	treatment,	when	
overgrowth	of	this	yeast	may	be	more	prevalent.			Similar	to	Raponi	et	al.	(2014),	
we	found	a	high	prevalence	of	C.	albicans	overgrowth	among	cases	infected	with	
ribotype	027.				This	association	merits	further	research	using	longitudinal	
studies.	
Our	study	was	somewhat	limited	by	the	moderate	sensitivity	of	our	toxin	
test	(95%	CI	87‐95	according	to	the	manufacturer	(23)).		We	chose	this	test	
because	our	purpose	was	to	identify	the	total	toxin	A	and	B	produced	in	the	stool,	
and	other,	more	sensitive	tests	such	as	a	cytotoxicity	assay,	only	detect	active	
toxin.		However,	our	sample	size	was	large,	and	the	association	between	spore	
and	toxin	production	was	strong	–	even	after	controlling	for	confounders.		
Further,	this	test	assured	that	if	we	were	able	to	identify	a	toxin‐spore	
correlation,	the	results	could	be	applied	to	infection	control	practices	in	
healthcare	settings,	as	it	can	easily	be	incorporated	in	clinical	laboratories	as	a	
proxy	of	spore	levels.				
In	conclusion,	in	vivo	toxin	and	spore	production	were	positively	and	
significantly	correlated	among	clinical	CDI	samples,	even	after	stratifying	by	
ribotype.		Therefore	–	as	is	already	standard	–contact	precautions	are	in	order	
for	all	individuals	with	CDI.		Nearly	all	of	our	patients	with	no	detectable	toxin	
production	shed	spores,	sometimes	at	significant	levels.		This	highlights	the	
complexity	of	diagnosis	and	prevention	of	a	condition	with	an	asymptomatic	
state	and	underscores	the	need	to	identify	alternative	therapies	and	control	
		 46
measures	that	better	address	not	only	the	health	of	an	infected	individual	but	the	
risk	to	others.						 	
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Table	3.1.	Distribution	of	toxin	and	spore	levels	by	ribotype	in	order	of	
prevalence	across	200	consecutive	CDI	positive	stool	samples	collected	from	the	
Microbiology	Reference	Laboratory	of	the	Saint	Joseph	Mercy	Health	System,	Ann	
Arbor,	MI.,	from	February	1st	to	July	20th,	2015.			
	
Ribotype		 n	(%) Normalized	
toxin	levels	
Median	(Range)	
Spore	levels
(CFU/g)	
Median	(Range)	
027	 31(19.0) 0.17(‐0.06‐3.94) 3.8x104(2.0x101	‐5.5x106)
014‐020	 26(16.0) 0.00(‐0.01‐0.51) 3.0x103(6.0x101‐4.0x105)
002	 9(5.5) 0.01	(‐0.05‐0.90) 4.0x104	(2.0x101–9.4x105)
053‐163	 8(4.9) 0.02(‐0.00‐2.33) 6.2x104(3.5x102‐2.2x106)
078‐126	 5(3.1) 0.32(‐0.02‐0.96) 7.5x104(7.5x101‐1.3x105)
015	 5(3.1) 0.00(‐0.01‐0.06) 2.6x104	(1.5x102‐1.5x104)
012	 2(1.2) 0.01(0.00‐0.01) 1.8x105(3.8x104‐3.8x105)
001	 1(0.6) 0.01(‐) 1.5x104(‐)	
003	 1(0.6) 1.48(‐) 8.1x105(‐)	
017	 1(0.6) 0.00(‐) 3.5x103(‐)	
Others*	 74(45.4) 0.01(‐0.06‐1.96) 3.3x104	(5.0x100‐2.3x106)
No	ribotype	data**	 37(18.5) 0.00(‐0.04‐1.96) 3.5x103(0‐1.4x106)
	
*	The	category	“Others”	includes	all	isolates	that	could	not	be	matched	to	a	reference	isolate.		
More	detail	on	this	category	can	be	found	in	the	appendix	(Table	S1).			
**	The	category	referred	as	“No	ribotype	data”	includes	stool	samples	from	which	C.difficile	could	
not	be	cultured	and	isolates	that	could	not	be	ribotyped.				
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Figure	3.1.	Laboratory	algorithm	used	throughout	this	study.	
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A.	
	
B.	
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Figure	3.2.			Distribution	of	spore	levels	by	toxin	levels	and	ribotype	across	200	
consecutive	CDI	positive	stool	samples	collected	from	the	Microbiology	
Reference	Laboratory	of	the	Saint	Joseph	Mercy	Health	System,	Ann	Arbor,	MI.,	
from	February	1st	to	July	20th,	2015.		Panel	A	shows	distribution	of	spore	levels	
by	categories	of	increasing	toxin	levels:	Non‐detectable	levels	(≤0.007	UA/mL),	
low	levels	(0.008‐0.367)	and	high	levels	(0.368‐3.941)	(Test	of	trend,	p<0.001).		
Panel	B	shows	distribution	of	spore	levels	across	categories	of	increasing	toxin	
levels	and	by	ribotype:	027/048	(Test	of	trend,	p<0.001),	014‐020	(Test	of	trend,	
p=0.10),	and	other	ribotypes	(Test	of	trend,	p<0.001).			
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Figure	3.3.		Difference	in	the	distribution	of	spore	levels	across	200	consecutive	
CDI	positive	stool	samples	by	CDI	laboratory	diagnosis	(toxin	Positive	(N=109))	
and	toxin	negative/PCR	positive	(N=	91)),	collected	from	the	Microbiology	
Reference	Laboratory	of	the	Saint	Joseph	Mercy	Health	System,	Ann	Arbor,	MI.,	
from	February	1st	to	July	20th,	2015	(t‐test,	p<0.001).	
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A.	
	 	
B.	
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C.	
	
	
Figure	3.4.		Difference	in	the	distribution	of	spore	levels	by	CDI	laboratory	
diagnosis	and	ribotype	across	200	consecutive	CDI	positive	stool	samples,	
collected	from	the	Microbiology	Reference	Laboratory	of	the	Saint	Joseph	Mercy	
Health	System,	Ann	Arbor,	MI.,	collected	from	February	1st	to	July	20th,	2015.		
Panel	A	includes	ribotypes	027/078	(t‐test,	p=0.04),	panel	B	includes	ribotype	
014‐020	(t‐test,	p=0.01),	and	panel	C	includes	all	other	ribotypes	(t‐test,	p=0.35).				
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Figure	3.5.	Distribution	of	spores	by	ribotype	across	200	consecutive	CDI	
positive	stool	samples	collected	from	the	Microbiology	Reference	Laboratory	of	
the	Saint	Joseph	Mercy	Health	System,	Ann	Arbor,	MI.,	from	February	1st	to	July	
20th,	2015.	Top	panel	includes	ribotypes	027/078	(n=36),	the	middle	panel	
includes	ribotype	014‐020	(n=26),	and	the	bottom	panel	includes	the	rest	of	the	
ribotypes	in	our	population	(n=101)	(ANOVA,	p=0.002)		
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Appendix	3.1.	Distribution	of	toxin	and	spore	levels	by	ribotype	across	200	
consecutive	CDI	positive	stool	samples	collected	from	the	Microbiology	
Reference	Laboratory	of	the	Saint	Joseph	Mercy	Health	System,	Ann	Arbor,	MI.,	
from	February	1st	to	July	20th,	2015.			
	
Ribotype		 N Normalized	toxin	levels
Median	(Range)	
Spore	levels	(CFU/g)
Median	(Range)	
027	 31 0.17(‐0.06‐3.94) 6.2x104(3.5x102‐2.2x106)
014‐020	 26 0.00(‐0.01‐0.51) 3.0x103(6.0x101‐4.0x105)
002	 9 0.01	(‐0.05‐0.90) 4.0x104	(2.0x101–9.4x105)
SJ485	 9 0.10(‐0.00‐0.83) 1.9x104(9.9x102‐4.2x105)
053‐163	 8 0.02(‐0.00‐2.33) 6.2x104(3.5x102‐2.2x106)
SJ420	 7 0.28(‐0.00‐1.35) 1.3x105(7.5x102‐1.4x106)
SJ308	 6 0.00(‐0.00‐0.29) 6.8x104(7.5x101‐2.2x106)
SJ467	 6 1.16(‐0.00‐1.58) 3.3x105(1.4x104‐2.3x106)
078‐126	 5 0.32(‐0.02‐0.96) 7.5x104(7.5x101‐1.3x105)
015	 5 0.00(‐0.01‐0.06) 2.6x104	(1.5x102‐1.5x104)
SJ311	 5 0.41(‐0.01‐1.96) 3.5x104(3.0x103‐2.6x106)
SJ406	 4 0.09(‐0.01‐1.15) 1.1x105(1.2x103‐8.5x105)
SJ435	 4 ‐0.01(‐0.04‐0.01) 1.2x104(1.5x102‐4.2x104)
SJ312	 3 0.00(‐0.06‐0.01) 8.5x103(3.5x101‐1.5x106)
SJ402	 3 0.62(0.00‐0.91) 2.5x104(2.0x103‐6.9x104)
SJ423	 3 0.00(‐0.00‐1.35) 4.3x104(6.0x103‐6.0x104)
012	 2 0.01(0.00‐0.01) 1.8x105(3.8x104‐3.8x105)
SJ310	 2 0.00(0.00‐0.00) 1.2x104(1.8x103‐2.2x104)
SJ409	 2 0.14(0.01‐0.27) 3.1x103(1.5x102‐6.0x103)
SJ413	 2 0.93(‐0.00‐1.86) 1.1x104(4.5x103‐2.2x105)
SJ428	 2 0.00(0.00‐0.00) 1.5x104(1.5x102‐4.2x104)
SJ443	 2 0.58(0.00‐1.15) 6.5x104(1.5x104‐1.2x105)
SJ451	 2 1.41(1.24‐1.58) 1.4x105(6.0x104‐2.2x105)
001	 1 0.01(‐) 1.5x104(‐)
003	 1 1.48(‐) 8.1x105(‐)
017	 1 0.00(‐) 3.5x103(‐)
SJ313	 1 0.00(‐) 3.1x104(‐)
SJ316	 1 0.00(‐) 5.0x103(‐)
SJ318	 1 1.59(‐) 2.6x105(‐)
SJ405	 1 0.12(‐) 3.6x105(‐)
SJ407	 1 0.00(‐) 5.1x103(‐)
SJ412	 1 0.02(‐) 1.2x105(‐)
SJ442	 1 1.82(‐) 1.6x104(‐)
SJ448	 1 0.00(‐) 2.5x102(‐)
SJ459	 1 0.01(‐) 5.0x100(‐)
SJ464	 1 0.00(‐) 1.5x102(‐)
SJ468	 1 0.02(‐) 3.8x104(‐)
SJ494	 1 0.80(‐) 1.0x104(‐)
No	ribotype	data**	 37 0.00(‐0.04‐1.96) 3.5x103(0‐1.4x106)
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Appendix	3.	2.		Median	levels	of	toxin	by	stool	consistency	across	200	
consecutive	CDI	positive	stool	samples	collected	from	the	Microbiology	
Reference	Laboratory	of	the	Saint	Joseph	Mercy	Health	System,	Ann	Arbor,	MI.	
from	February	1st	to	July	20th,	2015..	
	
**	Estimate	adjusted	for	age,	gender,	location	and	ribotype.				
	
	 	
Stool	
consistency	
N	 Normalized	toxin	
levels	
Median	(Range)	
OR	(95%	CI)* OR	Adj	(95%	CI)**
Soft		 81	 0.00(‐0.06‐3.94) 1.00(REF) 1.00(REF)	
Formed/	
Semi‐formed	
Mucoid	
Liquid		
	
16	
39	
64	
0.02(‐0.02‐1.96)	
0.28(‐0.05‐2.33)	
0.00(‐0.03‐1.52)	
1.64(0.60‐4.45)	
3.03(1.47‐6.24)	
0.78(0.38‐1.60)	
	
1.04(0.30‐3.60)	
3.90(1.69‐8.97)	
0.78(0.38‐1.59)	
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Appendix	3.	3.	Median	levels	of	spores	by	stool	consistency	across	200	
consecutive	CDI	positive	stool	samples	collected	from	the	Microbiology	
Reference	Laboratory	of	the	Saint	Joseph	Mercy	Health	System,	Ann	Arbor,	MI,	
from	February	1st	to	July	20th,	2015.			
	
Stool	
consistency	
N	 Spores	levels
(CFU/g)	
Median	(Range)	
Unit	
change	
in	spore	
levels*	
	
p	
value
Adj.	unit	
change	
in	spore	
levels**	
	
p	value	
Soft	 81	 2.5	x	104(0‐4.0x106) REF REF	
Formed/Semi
‐formed	
Mucoid	
Liquid	
	
16	
39	
64	
7.0x103(0‐2.4x106)	
6.2x104(0‐5.5x106)	
7.5x103(0‐2.8x106)	
2.35	
2.84	
0.38	
0.32	
0.07	
0.25	
	
1.76	
3.30	
0.63	
0.54	
0.05	
0.38	
	
	
*Unit	change	in	spore	levels	compared	to	soft	stool	consistency.	
**	Estimate	adjusted	for	age,	gender,	location	and	ribotype.				
	 	
		 61
Appendix	3.4.			Water	content	(%)	distributed	across	stool	consistency	across	
153	consecutive	CDI	positive	stool	samples	collected	from	the	Microbiology	
Reference	Laboratory	of	the	Saint	Joseph	Mercy	Health	System,	Ann	Arbor,	MI.,	
from	February	1st	to	July	20th,	2015.		Stool	consistency	was	classified	in	the	
following	four	categories:	formed/semi‐formed,	soft,	mucoid,	and	liquid	(Kruskal	
Wallis	Test,	p<0.001).			
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CHAPTER	IV	
Clinical	and	epidemiological	characteristics	of	toxin	negative/PCR	positive	
and	toxin	positive	C.	difficile	infection	patients.	
	
4.0.0.	Abstract		
	
Clostridium	difficile	is	associated	with	a	well–known	toxin‐mediated	
intestinal	disease,	C.	difficile	infection	(CDI);	however,	the	bacterium	is	also	
carried	asymptomatically	in	an	estimated	5%	of	healthy	individuals	and	in	an	
even	higher	percentage	of	hospitalized	patients.		Although	its	clinical	
applicability	is	still	controversial,	PCR	is	used	by	~44%	of	acute‐care	hospitals	in	
the	US	as	part	of	their	CDI	laboratory	algorithm.		A	limited	number	of	previous	
studies	suggest	that,	in	comparison	to	toxin	positive	individuals,	toxin	
negative/PCR	positive	patients	have	a	milder	CDI	presentation	that	resolves	
without	CDI	treatment.		This	study	aimed	to	determine	if	these	differences	could	
be	observed	among	a	population	with	high	CDI	treatment	rates.		In	addition,	as	
toxin	and	spore	levels	are	correlated,	we	sought	to	identify	host‐associated	
factors	with	fecal	spore	levels	in	CDI	patients.		In	a	population	with	92%	CDI	
treatment	rate,	we	observed	a	milder	CDI	presentation	among	the	91	toxin	
negative/PCR	positive	compared	to	120	toxin	positive	patients.		There	was	a	
strong	association	between	toxin	positivity	and	white	race,	and	CDI	severity	and	
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spore	levels.		These	results	will	help	improve	CDI	diagnosis	and	infection	and	
control	measures.			
	
4.1.0.		Introduction		
	
	Each	year,	Clostridium	difficile	causes	an	estimated	half	of	a	million	
infections	and	29,000	deaths	in	the	United	States	(US)	(1).		C.	difficile	infection	
(CDI)	is	characterized	by	a	wide	range	of	clinical	manifestations,	ranging	from	
mild	diarrhea	to	more	severe	disease	including	toxic	megacolon,	
pseudomembranous	colitis,	sepsis,	and	death	(2).		The	bacterium	is	carried	
asymptomatically	among	an	estimated	5%	of	healthy	individuals,	10%	of	
hospitalized	patients	in	acute	care	settings,	and	15%	of	patients	in	long‐term	
care	facilities	(3‐5).			
As	nosocomial	diarrhea	can	have	multiple	etiologies,	and	C.	difficile	
infection	does	not	necessarily	result	in	symptoms,	the	diagnosis	can	be	
complicated.		Thus,	the	laboratory	has	become	an	important	player	in	CDI	
diagnosis.		However,	particularly	in	the	US,	there	is	not	one	agreed	upon	
laboratory	algorithm	recommended	for	clinical	settings	(6).		
The	Society	for	Healthcare	Epidemiology	of	America	and	the	Infectious	
Diseases	Society	of	America	(SHEA/IDSA)	and	the	American	College	of	
Gastroenterology	recommend	a	multi‐step	laboratory	algorithm	starting	with	the	
detection	of	glutamate	dehydrogenase	(GDH),	followed	by	either	a	confirmatory	
test	for	detection	of	toxin	using	an	Enzyme	Immunoassay	(EIA)	or	a	Cell	
Cytotoxicity	Assay	(CCTA)),	or	detection	of	the	toxigenic	bacteria	through	PCR	or	
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cytotoxigenic	culture	(CC)	(7‐9).		CCTA	and	CC	are	considered	C.	difficile	
reference	laboratory	methods;	however,	they	are	labor‐intensive	and	have	a	
slow‐turn	around	(10),	and	as	such	are	not	suitable	for	CDI	clinical	diagnosis.		
Due	to	their	limited	sensitivity,	toxin	EIA	techniques	are	not	considered	
appropriate	as	sole	diagnostic	tests	(8).	By	contrast,	PCR	is	considered	suitable	as	
a	confirmatory	CDI	test,	as	it	has	both	high	sensitivity	and	specificity	(8).		
However,	the	PCR	test	targets	the	toxins’	genes	rather	than	the	toxins	
themselves,	which	does	not	allow	differentiation	between	CDI	symptomatic	and	
asymptomatic	individuals	(11,	12).			
In	2014,	44%	of	acute	care	hospitals	participating	in	the	National	
Healthcare	Safety	Network	(NHSN)	reported	using	molecular	tests	(PCR)	alone	
or	in	combination	with	other	tests	for	diagnosis	of	CDI	(13).	The	implementation	
of	this	more	sensitive	test	has	led	to	increases	of	between	50	and	100%	in	CDI	
reported	rates	(13).		Considering	that	colonization	with	C.	difficile	is	5‐10	times	
more	common	than	CDI,	and	that	C.	difficile	is	responsible	for	only	~20%	of	all	
nosocomial	diarrheas,	it	is	likely	that	some	patients	diagnosed	as	CDI	positive	
using	a	PCR	test	have	diarrhea	of	a	different	etiologic	origin	(13,	14).		
A	limited	number	of	studies	have	compared	the	clinical	and	
epidemiological	differences	between	CDI	patients	by	laboratory	diagnostic	
criteria.		While	not	consistent	across	studies	(15),	most	previous	studies	
observed	clinical	and	epidemiological	differences	between	patients	with	
detectable	levels	of	toxin	(through	EIA	or	CCTA)	and	those	diagnosed	only	
through	the	detection	of	toxigenic	C.	difficile	strains	(PCR	or	CC)	(12,	15,	16).			
Baker	et	al.	(2013)	reported	that	toxin	negative/PCR	positive	(toxin‐/PCR+)	
patients	(n=53)	had	significantly	lower	14	days‐all‐cause	mortality	than	toxin	
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positive	(toxin+)	patients	(n=24)	(16).		Moreover,	even	though	only	15%	of	the	
toxin‐/PCR+	patients	received	CDI	treatment,	97%	of	them	had	resolved	their	
diarrhea	after	14	days	(16).		Similarly,	Polage	et	al.	(2015)	reported	toxin‐/PCR+	
patients	(n=	162)	had	similar	outcomes	as	CDI	negative	patients	(n=1123),	even	
though	only	41%	of	toxin‐/PCR+	patients	received	CDI	treatment	(13).		Longtin	
et	al.	(2013)	also	observed	that	only	3%	of	PCR+	(n=85)	developed	CDI	
complications	in	comparison	to	39%	toxin+	patients	(n=56)	(17).		This	study	also	
reported	similar	associations	with	CDI	recurrence	and	30‐days	mortality	(17).			
Longtin	and	colleagues	did	not	specify	the	percent	of	PCR	positive	
patients	who	were	treated	with	vancomycin	or	metronidazole	(17).		However,	as	
their	routine	CDI	laboratory	algorithm	used	solely	PCR,	we	can	assume	their	
study	population	consisted	of	a	higher	percent	of	treated	PCR+	patients	than	in	
the	previously	mentioned	studies	where	the	PCR	was	not	part	of	the	regular	
clinical	algorithm	(13,	16).		However,	as	CDI	treatment	may	obscure	or	
exacerbate	differences	in	clinical	severity,	our	study	aimed	to	determine	if	the	
previously	described	clinical	and	epidemiological	differences	between	toxin‐
/PCR+	and	toxin+	CDI	patients	were	observed	among	a	population	with	high	CDI	
treatment	rates.			
	 	As	we	also	reported	in	Chapter	III	of	this	dissertation,	toxin	production	is	
correlated	with	spore	production;	however,	both	toxin+	and	toxin‐/PCR+	CDI	
patient	can	shed	spores	(15,	18).			We	further	investigated	the	host‐associated	
characteristics	of	spore	production.		As	far	as	we	know,	this	is	the	first	study	
specifically	investigating	host‐associated	factors	impacting	spore	stool	levels	in	
CDI	patients.		
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4.2.0.		Methods	
Study	population		
	
	 We	conducted	a	case‐control	study	of	CDI	patients	receiving	care	at	Saint	
Joseph	Mercy	Hospital	(SJMH),	an	acute	care	hospital	in	Ann	Arbor,	MI.		
The	Institutional	Review	Boards	at	SJMH	and	the	University	of	Michigan	(IRB	
Health	Sciences	and	Behavioral	Sciences)	approved	our	study	protocol.	
Our	study	is	composed	of	two	sets	of	populations.		First,	we	included	all	
hospitalized	patients	aged	18	and	older	who	were	laboratory	diagnosed	with	CDI	
based	on	SJMH	laboratory	guidelines	from	January	1st	through	June	30th,	2014.	
To	research	the	association	between	spore	levels	and	disease	severity,	we	
included	all	patients	with	the	same	characteristics	who	were	hospitalized	
between	February	1st	and	July	20th	2015,	for	whom	we	possessed	a	positive	CDI	
stool	sample	from	a	previous	study	(Figure	4.6).			
The	SJMH	CDI	laboratory	algorithm	includes	an	initial	GDH/Toxins	AB	
screening	using	C.DIFF	QUIK	CHEK	COMPLETE®	(Alere,	Waltham,	MA./Techlab,	
Blacksburg,	VA.).		In	case	of	indeterminate	results,	samples	are	further	tested	for	
presence	of	the	toxin	B	gene	using	a	tcdB	PCR	assay	(Cepheid	Gene	Xpert®,	
Sunnyvale,	CA.).		A	positive	CDI	result	is	reported	in	case	of	two	positive	test	
combinations:	1)	GDH	positive	and	toxin	positive	(toxin+),	or	2)	GDH	positive,	
toxin	negative	and	PCR	positive	(toxin‐/PCR+).		Based	on	this	classification,	we	
defined	cases	as	toxin+	patients	and	toxin‐/PCR+	patients	as	controls.		In	case	of	
successive	tests	of	the	same	individual,	we	included	only	their	first	CDI	positive	
case	during	the	study	period.			
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Data	collection	
	
We	gathered	several	epidemiological,	clinical,	laboratory,	and	treatment	
variables	from	the	medical	record.		Variables	included	details	and	dates/times	of	
CDI	test	results	and	CDI	treatment;	use	of	antibiotics,	H2	receptors	antagonists	
(H2	blockers),	proton	pump	inhibitors	(PPI),	corticosteroids,	and	chemotherapy	
during	the	90	days	before	sample	collection;	use	of	laxatives	in	the	week	before	
sample	collection;	and	history	of	hospitalization,	surgery,	or	CDI	diagnoses	in	the	
90	days	before	sample	collection.		CDI	severity	was	evaluated	based	on	age,	latest	
levels	of	white	blood	cells	(WBC)	and	serum	creatinine	before	initiation	of	CDI	
treatment	(compared	to	baseline	levels	in	the	last	year),	and	ICU	stay	due	to	CDI	
during	the	current	episode.		We	used	the	SHEA/IDSA	guidelines	to	classify	CDI	
severity	as:	mild,	moderate,	severe,	and	severe	and	complicated	(7).		
Through	an	electronic	data	abstraction,	we	collected	demographic	
characteristics	(age,	gender,	race	based	on	self‐reporting),	length	of	stay,	
Charlson	Comorbidity	Score,	an	institution‐specific	retrospective	30‐days	
mortality	risk	(19,	20).		Charlson	Comorbidity	Score	is	a	validated	estimator	of	
risk	of	death	from	comorbid	disease:	the	higher	the	score	the	higher	the	risk	
(21).	By	contrast,	the	institutional‐specific	30‐days	mortality	risk	uses	the	lowest	
stratum	(ei.	risk	stratum	1)	to	indicate	the	highest	mortality	risk	and	the	highest	
stratum	(ei.	risk	stratum	5)	to	indicate	the	lowest	risk	of	mortality	(19,	20).	In	
addition,	we	recorded	all‐cause	and	CDI‐associated	readmission	within	30	days	
from	discharge,	and	all‐cause	and	CDI‐associated	mortality	within	30‐days	of	CDI	
diagnosis	(utilizing	the	Michigan	Death	Index).	
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Determination	of	spore	levels	
	
Spore	levels	were	quantified	in	stool	samples	available	for	a	subset	of	our	
study	population	(Figure	4.6).		Following	a	heat	treatment	(65oC	for	20	minutes),	
spore	levels	were	quantified	by	culturing	serial	dilutions	of	the	fecal	specimen	on	
Cycloserine	Cefoxitin	Fructose	Agar	with	Horse	Blood	and	Taurocholate	
(Anaerobe	Systems,	Morgan	Hill,	CA.)	for	24	hours	at	37oC	under	anaerobic	
conditions.		Spore	levels	were	reported	as	colony‐forming	units	(CFU)	per	gram	
of	feces.			
	
Ribotyping	of	C.difficile	isolates	
	
A	fluorescent	PCR	ribotyping	technique	using	capillary	gel	electrophoresis	
was	performed	to	ribotype	the	C.	difficile	isolates	recovered	from	our	study	
samples	as	previously	described	(22).				
	
Statistical	analysis	
	
Chi‐square	or	the	Mann	Whitney	test	was	performed	to	determine	the	
presence	of	significant	differences	between	cases	and	controls	with	respect	to	
demographic	characteristics,	CDI	severity,	CDI	risk	factors,	CDI	treatment	and	
clinical	outcome.	Cochran‐Armitage	Trend	Test	was	used	to	evaluate	linear	
treads	across	the	variables	and	frequency	of	cases.		We	further	fitted	univariate	
and	multivariate	logistic	regression	models	to	estimate	the	strength	of	the	
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associations	between	selected	variables	and	toxin+	versus	toxin‐/PCR+	patients.		
For	the	subset	of	the	study	population	(n=77)	where	spore	levels	were	known,	
we	used	univariate	and	multivariate	linear	regression	to	model	the	log‐
transformed	average	level	of	spores	in	relation	to	known	CDI	risk	factors	and	
other	epidemiological	and	clinical	characteristics.		Stepwise	regression	(with	a	
significance	level	of	entry	and	stay	equaled	to	0.30	and	0.35	respectively)	and	
previous	knowledge	from	the	literature	informed	the	selection	of	variables	for	
the	multivariate	models.		SAS	9.4	(Cary,	NC.)	and	STATA	14	(College	Station,	TX.)	
were	used	to	perform	all	analysis	and	graphics.		
	
4.3.0.		Results		
	
	 Of	211	CDI	hospitalized	patients,	120	(56.9%)	were	toxin+	and	193	
(91.5%)	had	receipt	of	CDI	treatment	recorded	in	their	medical	record.		Toxin+	
patients	were	slightly	older	than	toxin‐/PCR+	patients	(OR=	1.02,	95%	CI	1.00‐
1.04),	but	gender	distributions	were	similar	(Table	4.2).		Whites	were	twice	as	
likely	as	blacks	or	multiracial	patients	to	be	toxin+	(OR=2.11	(95%CI	1.00‐4.46).		
This	association	remained	after	adjustment	for	age,	creatinine	and	WBC	levels,	
CDI	severity,	previous	use	of	antibiotics,	PPI,	corticosteroids,	laxatives	and	
chemotherapy,	previous	surgery	and	CDI	episode,	and	30‐days	all‐cause	
mortality	(OR=	2.12;	95%	CI		0.92‐4.88)	(Table	4.3).				
Using	SHEA/IDSA	guidelines	to	classify	severity,	toxin+	patients	had	a	
more	severe	CDI	presentation	than	toxin‐/PCR+	patients.		Although	not	
statistically	significant,	severe	and	complicated	CDI	cases	were	more	likely	to	be	
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toxin+	(OR=2.20,	95%	CI	(0.68‐7.13).		Further,	as	CDI	severity	increased,	the	
number	of	toxin+	patients	increased	(test	for	trend	p=0.11)	(Figure	4.7).			
Toxin+	patients	also	tended	to	be	more	ill	than	toxin‐/PCR+	patients,	
having	a	slightly	higher	Charlson	Comorbidity	Score	(OR=1.30	(95%	CI	0.93‐
1.36).		In	addition,	the	proportion	toxin+	cases	increased	with	the	comorbidity	
score	(test	of	trend	p=0.22)	(Figure	4.7).		Further,	toxin+	patients	had	a	higher	
risk	of	30‐days	mortality	(lower	strata	indicates	higher	risk	of	mortality)		
(OR=0.79	(95%	CI	0.62‐1.00).		As	mortality	risk	increased,	the	percent	of	toxin+	
patients	increased	(test	of	trend	p=0.06)	(Figure	4.7).		Although	we	did	not	
observe	a	significant	difference	in	all‐cause	30‐days	readmission	or	mortality	by	
toxin	status,	all	four	patients	with	a	CDI‐associated	death	were	toxin+.			
	 In	regards	to	CDI	risk	factors,	we	did	not	find	a	strong	association	
between	previous	antibiotic	history	and	toxin+	patients	(OR=1.40	(95%	CI	(0.69‐
2.84)).		However,	users	of	macrolides	during	the	3	months	prior	to	sample	
collection	were	1.93	(95%	CI	0.84‐4.45)	times	more	likely	to	be	a	toxin+,	whereas	
penicillin	(OR=0.53;	95%	CI:	0.28,	1.01)	and	carbapenems	users	(OR=0.40;	95%	
CI:	0.13‐1.23)	were	less	common	in	toxin+	than	toxin‐/PCR+	patients	(Table	4.2).	
Previous	use	of	H2	blockers,	hospitalization,	and	surgery	also	tended	to	be	more	
common	among	toxin+	than	toxin‐/PCR+	patients	(Table	4.2).		Although	only	
recorded	for	a	subset	of	our	population	(n=77),	enteral	tube	use	was	less	
common	among	toxin+	patients	(p=0.17).			
	 Among	the	subset	of	our	study	population	(n=77),	where	spore	levels	in	
stool	were	available,	we	identified	a	strong	positive	association	between	spore	
levels	and	history	of	hospitalization	(Table	4.4.).		Spore	levels	tended	to	increase	
with	history	of	antibiotic	use	during	the	previous	90	days,	but	the	association	
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was	not	statistically	significant.		Use	of	lincosamides	(ei.	clindamycin)	(p=0.05)	
was	negatively	associated	with	spore	levels,	as	was	a	history	of	previous	
chemotherapy	(p=0.004).		History	of	hospitalization	(p=0.06)	and	Charlson	
Comorbidity	Score	(p=0.05)	remained	associated	to	spore	levels	even	after	
adjusting	for	gender,	Charlson	Comorbidity	Score,	30‐days	mortality	risk,	
complicated	CDI	severity,	use	of	enteral	tube,	history	of	antibiotics,	PPI,	
chemotherapy,	hospitalization	as	necessary	(Table	4.4).			
We	observed	a	strong	association	between	spore	levels	and	CDI	severity,	
particularly	among	severe/complicated	individuals	(p=0.33)	(Table	4.4,	Figure	
4.8).		This	association	remained	significant	after	adjusting	for	confounders.		
However,	when	we	stratified	by	ribotype,	the	association	decreased	and	was	no	
longer	statistically	significant,	but	we	note	that	the	sample	size	was	also	severely	
reduced	(Figure	4.8).			
	
4.4.0.		Discussion		
	
In	a	comparison	of	hospitalized	CDI	patients	with	and	without	a	positive	
stool	test	for	toxin,	CDI	severity,	Charlson	Comorbidity	Score,	30‐days	mortality	
risk,	and	white	race	were	strongly	associated	with	detection	of	toxin.		When	we	
did	not	consider	presence	of	toxin,	we	also	observed	an	association	of	spore	
levels	with	CDI	severity.			
	 We	found	no	previous	reports	confirming	or	refuting	our	observation	that	
specifically	increased	fecal	spore	levels	in	clinical	samples	–omitting	the	in	vitro	
analysis	step	‐	are	associated	with	increased	CDI	severity	and	30‐days	all	cause	
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mortality.		However,	our	finding	is	consistent	with	the	hypothesis	that	greater	
spore	production	is	likely	to	be	associated	with	the	presence	of	more	vegetative	
cells	(23)‐‐	hence,	greater	toxin	levels	when	produced.		Consistent	also	with	our	
results,	in	a	study	of	106	clinical	isolates,	Carlson	et	al.	(2013)	previously	linked	
in	vitro	spore	production	to	CDI	severity	(23).		Furthermore,	spore	production	
was	higher	among	individuals	with	known	CDI	risk	factors:	previous	history	of	
antibiotics,	proton	pump	inhibitors,	and	previous	hospitalization	(24).			
The	association	of	CDI	severity	and	toxin	detection	is	consistent	with	
previous	studies	(13,	16,	17,	25).			However,	unlike	previous	reports,	toxin+	CDI	
cases	were	no	more	likely	than	toxin‐/PCR+	CDI	cases	to	be	re‐admitted	within	
30	days	of	discharge	or	to	die	within	30	days	post	CDI	diagnosis	(16,	17,	26).		
This	may	be	due	to	differences	in	classification	schemes	(not	all	used	toxin‐
/PCR+	as	a	reference	(26)),	outcome	definitions,	study	population,	or	treatment	
regimen.		Unlike	previous	studies	(13,	16,	26),	the	majority	of	our	participants	
received	CDI	treatment.			
Similar	to	previous	studies,	toxin+	and	toxin‐/PCR+	CDI	patients	did	not	
differ	by	age	and	gender	(13,	14).		However,	we	did	observe	a	strong	association	
between	white	race	and	Toxin+	CDI	cases	(OR=	2.11	(95%	CI	1.00‐4.46)).		
Although	a	positive	association	between	white	race	and	CDI	occurrence	has	been	
reported	previously	(1,	27,	28),	we	found	no	previous	reports	of	an	association	of	
race	and	toxin	positivity.				
It	is	most	likely	that	white	race	is	a	marker	for	CDI	risk	factors.		In	the	US,	
white	individuals	generally	have	better	access	and	quality	of	healthcare	than	
others	(29),	which	make	them	more	likely	to	have	access	to	treatments	that	are	
CDI	risk	factors	(30).		Indeed,	those	of	white	race	were	more	likely	to	report	
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previous	use	of	H2	blockers,	PPI,	and	chemotherapy‐‐all	previously	described	
CDI	risk	factors	(7,	24,	31,	32).		However,	the	association	between	toxin	positivity	
and	white	race	in	our	study	population	remained	after	adjusting	for	several	risk	
factors	and	case	severity.	This	association	deserves	further	scrutiny.			
Our	results	add	to	growing	evidence	questioning	the	clinical	applicability	
of	including	PCR	testing	as	part	of	CDI	laboratory	analysis	(6,	13).		If	toxin‐/PCR+	
patients	have	a	milder	CDI	presentation	and	are	able	to	resolve	their	diarrhea	
without	further	treatment	(16),	the	question	arises	whether	CDI	treatment	is	
advisable.		Due	to	the	disruption	of	the	gut	microbiota,	treatment	of	
asymptomatic	carriers	can	increase	spore	shedding	and	symptomatic	CDI	
occurrence	(33‐34).		Further,	anti‐anaerobic	therapies	such	as	vancomycin,	can	
promote	the	selection	and	spread	of	vancomycin‐resistant	enterococcus	
colonization	(35,	36).		Finally,	as	the	PCR	test	cannot	distinguish	between	
colonizing	isolates	and	disease,	the	number	of	diagnoses	and	associated	
treatment	will	increase.		Indeed,	following	the	introduction	of	molecular	testing,	
the	number	of	reported	CDI	cases	has	increased	by	as	much	as	100%	in	some	
hospitals	(13,	17).		Furthermore,	CDI	rates	are	now	used	as	a	healthcare	quality	
indicator	and	as	there	is	no	single	recommended	CDI	laboratory	algorithm	in	the	
US,	the	use	of	PCR	by	some	but	not	all	laboratories	may	confound	the	ability	to	
appropriately	compare	performance	across	healthcare	settings	(6).		
Nevertheless,	the	increased	sensitivity	of	PCR	testing	can	aid	infection	control;	
CDI	spores	are	found	in	toxin‐/PCR+	stools,	although	the	average	levels	are	
significantly	lower	than	for	toxin+	CDI	patient,	as	reported	in	a	previous	chapter.					
To	prevent	overdiagnosis	and	overtreatment,	the	United	Kingdom	has	
implemented	a	different	algorithm	that	might	be	considered	elsewhere.		The	
		 74
algorithm	recommends	PCR	as	part	of	its	CDI	lab	algorithm;	however,	it	is	used	
for	screening	purposes	only.		All	stool	samples	are	processed	initially	using	PCR;	
then,	a	sensitive	toxin	EIA	follows	for	PCR	positive	samples.		Only	if	the	EIA	test	
for	toxin	is	positive	is	the	CDI	positive	result	reported	to	the	physician.		Toxin‐
/PCR+	patients	are	reported	only	to	the	Infection	Control	Unit	for	further	
analysis	(37).		
	 In	conclusion,	in	our	study	population,	toxin	‐/	PCR	+	CDI	patients	were	
less	ill,	had	lower	30‐days	mortality	risk,	and	shed,	on	average,	lower	levels	of	
spores.		However,	we	did	observe	an	increase	in	CDI	severity	with	spore	levels,	
particularly	among	severe	and	complicated	CDI	patients.		These	findings	raise	
questions	regarding	use	of	the	PCR	test	for	clinical	purposes	as	opposed	to	
infection	control.		Alternative	CDI	diagnostic	algorithms	should	be	evaluated	to	
compare	the	trade‐offs	in	terms	of	patient	risk	and	benefit,	infection	control,	and	
cost.				
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Table	4.2.		Distribution	of	toxin	positive	(n=120)	and	toxin	negative/PCR	
positive	CDI	patients	across	demographic,	epidemiological,	severity,	and	clinical	
characteristics,	Saint	Joseph	Mercy	Hospital,	Ann	Arbor,	MI.,	January	1st	–July	
30th,	2014/February	1st	to	July	20th,	2015.	
	
	 Group,	n	(%)/mean	(SD) Toxin	Positive	vs.	
	 M	 Toxin	Positive
N=	120	
PCR	Positive
N=	91	
p
	
OR	 95%	CI
Demographics	
Age	(years)	 	 69.13(15.86) 63.79(16.99) 0.03	 1.02	 1.00‐1.04
Gender	
		Female	
	
67(55.83)	 50(54.95)	 0.90	
	
1.04	 0.60‐1.79	
Race	
			White	
			Black	or		
						Multiracial		
1	
105(88.24)	
	
14(11.76)	
71(78.02)	
	
20(21.98)	
0.10	 2.11	 1.00‐4.46
Risk	factors	(90	days	before	CDI	sample	collection)
Antibiotic	history		 	 101(84.17) 72(79.12) 0.34	 1.40	 0.69‐2.84
			Penicillins	 	 23(19.17) 28(30.77) 0.05	 0.53	 0.28‐1.01
			Cephalosporins	 	 81(67.50) 62(68.13) 0.92	 0.97	 0.54‐1.74
			Carbapenems	 	 5(4.17) 9(9.89) 0.10	 0.40	 0.13‐1.23
			Macrolides	 	 21(17.50) 9(9.89) 0.12	 1.93	 0.84‐4.45
			Quinolones	 	 23(19.17) 19(20.88) 0.75	 0.90	 0.46‐1.77
			Sulfonamides	 	 7(5.83) 4(4.40) 0.64	 1.35	 0.38‐4.75
			Tetracyclines	 	 1(0.83) 0(0) 0.38	 	
			Aminoglycosides	 	 5(4.17) 4(4.40) 0.94	 0.95	 0.25‐3.63
			Lincosamides	 	 18(15.00) 9(9.89) 0.27	 1.61	 0.69‐3.77
			Glycopeptides	 	 62(51.67) 41(45.05) 0.34	 1.30	 0.76‐2.25
			Amebicides	 	 45(37.50) 36(39.56) 0.76	 0.92	 0.52‐1.60
H2	blockers		 	 49(40.83) 28(30.77) 0.13	 1.55	 0.87‐2.76
Proton	pump	inhibitor		 	 57(47.50) 49(53.85) 0.36	 0.78	 0.45‐1.34
Corticosteroids		 	 40(33.33) 30(32.97) 0.96	 1.02	 0.57‐1.81
Chemotherapy	 	 9(7.50) 5(5.49) 0.56	 1.40	 0.45‐4.31
Previous	
hospitalization	
	 78(65.00) 52(57.14) 0.25	 1.39	 0.80‐2.44
Previous	surgery	 	 43(35.83) 24(26.37) 0.14	 1.56	 0.86‐2.83
Previous	CDI	episode	 	 17(14.17) 10(10.99) 0.49	 1.34	 0.58‐3.08
Use	of	laxatives	
(Previous	week)	
	 52(43.33) 30(32.97) 0.13	 1.56	 0.88‐2.74
Enteral	tube	(Current	
encounter)**	
7
0	
1(2.56) 4(10.00) 0.17	 0.24	 0.03‐2.22
Length	of	hospital	stay	
before	CDI	test	order	
(Current	
encounter)(days)	
	 3.52(4.67) 2,83(6.32) 0.70	 1.02	 0.97‐1.08
CDI	severity	
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WBC	(thou/mcL)	 	 13.48(7.76) 11.81(8.57) 0.02	 1.03	 0.99‐1.07
Creatinine	(mg/dL)	 	 1.42(1.19) 1.92(2.36) 0.84	 0.85	 0.72‐1.00
30‐days	Mortality	risk	 	 2.42(1.09) 2.72(1.18) 0.06	 0.79	 0.62‐1.00
Charlson	Comorbidity	
Score		
2	 2.17(1.53) 1.91(1.42) 0.19	 1.13	 0.93‐1.36
CDI	severity	 	 	
			Mild	 	 25(20.83) 24(26.37) 0.34	 0.74	 0.39‐1.40
			Moderate	 	 38(31.67) 33(36.26) 0.48	 0.81	 0.46‐1.45
			Severe	 	 46(38.33) 32(32.97) 0.42	 1.26	 0.71‐2.22
			Severe	and	
complicated	
	 11(9.17) 4(4.40) 0.18	 2.20	 0.68‐7.13
Clinical	outcomes	
Length	of	stay	(days)	 	 9.47(8.86) 8.2(7.81) 0.14	 1.02	 0.98‐1.05
ICU	stay	 1	 39(32.77) 25(27.47) 0.41	 1.29	 0.71‐2.34
Total	Cost		(Dollars)	 2	 63,381(84,024) 52,307(60,508) 0.19	 	
Received	CDI	
Treatment	
	 111(92.50) 82(90.11) 0.54	 1.35	 0.52‐3.56
			Metronidazole	 	 56(46.67) 43(47.25) 0.93	 0.98	 0.56‐1.69
			Vancomycin		 	 95(79.17) 63(69.23) 0.10	 1.69	 0.90‐3.16
Readmission	within	30	
days	of	discharge	(All	
cause)	
	 26(21.67) 21(23.08) 0.81	 0.92	 0.48‐1.77
Death	within	30	days	
of	CDI	diagnosis			
(All	cause)	
	 13(10.83) 13(14.29) 0.45	 0.73	 0.32‐1.66
				Death‐associated	to	
CDI	*	
1	 4(100%) 0(0) 0.04	 4.05	
		
**	Among	a	subset	of	our	population	(n=77).			
	 *	Among	those	individual	who	died	30	days	after	CDI	diagnosis	
Among	those	patients	who	received	CDI	treatment	
			M	column	represent	missing	values	in	each	category	
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Table	4.3.		Association	between	white	race	and	demographic,	epidemiological,	
clinical,	and	severity	characteristics	of	CDI	positive	patients	(N=211),	Saint	
Joseph	Mercy	Hospital,	Ann	Arbor,	MI.,	January	1st	–July	30th,	2014/February	1st	
to	July	20th,	2015.	
	
	 Odds	Ratio	 95% CI		
Demographics	
Age	 1.01 0.99‐1.04
Gender	 1.32 0.63‐2.75
Risk	factors	(90	days	before	CDI	sample	collection)
H2	Blockers	 1.44 0.65‐3.20
Proton	Pump	Inhibitor	 1.77 0.56‐2.46
Laxatives	(previous	week) 0.76 0.36‐1.60
Corticosteroids	 0.67 0.31‐1.42
Chemotherapy	 2.63 0.33‐20.82
Previous	hospitalization	 0.87 0.40‐1.86
Previous	surgery	 0.81 0.37‐1.75
Previous	CDI	episode	 0.83 0.29‐2.36
Previous	antibiotic	history	 0.56 0.18‐1.69
Severity	and	clinical	outcomes
WBC	(thou/mcL)	 1.08 1.01‐1.15
Creatinine	(mg/dL)	 0.82 0.69‐0.97
30‐days	mortality	risk	 1.14 0.82‐1.58
Charlson	Comorbidity	
Score	
0.84 0.66‐1.07
CDI	severity		
			Mild	 0.82 0.35‐1.19
			Moderate	 0.42 0.97‐0.33
			Severe	 0.66 0.31‐1.38
			Severe	and	complicated 2.85 0.36‐22.42
Length	of	stay	(days)	 0.98 0.95‐1.02
Readmission	within	30	
days	of	discharge	
(All	cause)	
0.93 0.39‐2.21
Mortality	within	30	days	
of	CDI	diagnosis		
(All‐cause)		
0.79 0.27‐2.52
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Table	4.4.		Unit	change	of	spore	levels	by	demographic,	epidemiological	and	
severity	and	clinical	characteristics	(N=77)	of	CDI	positive	patients,	Saint	Joseph	
Mercy,	Ann	Arbor,	MI.,	February	1st	to	July	20th,	2015.			
	
	
	 Univariate	analysis	 Multivariate	analysis*
	 Unit	change	in	
spore	levels	by	one	
unit	
change/compared	
to	reference	group	
p	 Unit	change	in	spore	
levels	by	one	unit	
change/compared	to	
reference	group	
p
Demographics	
Age	(years)	 1.00 0.93 	
Gender		
		Female	 0.45	 0.28	
	
0.52	 0.41	
Race	
		White		 0.96	 0.97	
	
Risk	factors	(90	days	before	CDI	sample	collection)
Antibiotic	history		 2.74 0.24 0.28	 0.22
H2	Receptor	Blocker	use		 1.69 0.50 	
Proton	Pump	Inhibitor	use	 1.88 0.40 1.35	 0.71
Corticosteroid	use		 1.64 0.51 	
Chemotherapy	 0.16 0.004 0.12	 0.21
Previous	hospitalization	 8.12 0.73 5.47	 0.06
Previous	surgery		 0.75 0.73 	
Previous	CDI	episode	 2.58 0.37 0.63	 0.70
Laxatives	(previous	week)	 1.37 0.68 	
Enteral	tube	 5.82 0.24 4.10	 0.36
Severity	and	clinical	outcomes
WBC	(thou/mcL)	 1.05 0.45 	
Creatinine	(mg/dL)	 1.11 0.52 	
30‐days	Mortality	risk		 0.60 0.12 	
Charlson	Comorbidity	Score	 2.22 0.01 1.91	 0.05
CDI	severity		 	
			Mild	 0.61 0.56 	
			Moderate	 0.62 0.55 	
			Severe	 1.65 0.52 	
			Severe	and	complicated	 5.09 0.33 2.55	 0.61
Length	of	stay	(days)	 1.05 0.30 	
Readmission	within	30	days	
of	discharge		
(All	cause)	
1.31 0.76 	
Death	within	30	days	of	CDI	
diagnosis		
(All	cause)	
5.37 0.22 1.63	 0.75
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*	Multivariate	model	included	the	following	variables:	gender,	history	of	antibiotics,	proton	pump	
inhibitors,	chemotherapy,	hospitalization,	and	CDI,	Charlson	Comorbidity	Score,	complicated	CDI	severity,	
use	of	enteral	tube	during	current	encounter,	and	30‐days	mortality.			
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Figure	4.6.	Distribution	of	study	population	across	laboratory	diagnosis	and	
spore	data	availability.			
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A.	
	B.		
B.	 	
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C.				
		
Figure	4.7.		Distribution	of	study	participants	by	laboratory	diagnosis	(percent):	
A)	across	categories	of	30‐days‐	mortality	risk	(lower	strata	indicates	higher	risk	
of	mortality)(test	of	trend,	p=0.06)	B)	across	categories	of	Charlson	Comorbidity	
Score	(higher	strata	indicates	more	morbidity)(test	of	trend,	p=	0.22),	C)	across	
categories	of	CDI	severity	(test	of	trend,	p=0.11).
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.A.	
	
B.		
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Figure	4.8.		Distribution	of	log‐transformed	spores:	A)	across	CDI	severity	(Test	
of	trend	p=0.26),	and	B)	across	CDI	severity	and	C.difficile	ribotypes:	ribotype	
027/078	(n=16,	Test	of	trend,	p=0.89),	ribotype	014‐020	(n=9,	Test	of	trend	
p=0.85),	and	other	ribotypes	(n=39,	Test	of	trend,	p=0.25).		
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CHAPTER	V	
An	in	silico	evaluation	of	treatment	regimens	for	recurrent	Clostridium	
difficile	infection	
	
5.0.0.		Abstract:	
	 Clostridium	difficile	infection	(CDI)	is	one	the	leading	causes	of	nosocomial	
infection	in	the	United	States.		Although	effective	treatment	is	available,	up	to	
35%	of	infections	recur.		Risk	of	CDI	varies	by	ribotype,	with	some	of	the	
variation	in	risk	attributed	to	differences	in	sporulation	and	germination	rates.		
However,	whether	sporulation	and	germination	rates	mediate	effectiveness	of	
treatment	and	risk	of	recurrence	remains	unclear.		Recommended	treatments	for	
repeated	recurrence	include	tapering	or	pulsing	of	oral	vancomycin.			Although	
clinical	trials	show	tapered/pulsed	vancomycin	treatment	to	be	more	effective	at	
reducing	CDI	recurrence	than	the	standard	longer	and	higher	doses,	no	
controlled	data	exist	evaluating	the	relative	effectiveness	of	these	regimens.	In	
the	absence	of	a	controlled	trial,	an	in	silico	model	can	provide	useful	insights.		
Therefore,	we	developed	a	compartmental	in‐host	mathematical	model	of	CDI,	
composed	of	vegetative	cells,	toxins,	and	spores.	We	created	both	deterministic	
and	stochastic	versions	to	determine	the	role	of	sporulation/germination	
patterns	in	recurrence	and	the	effectiveness	of	current	tapered/pulsed	
vancomycin	regimens	by	ribotype.		Our	models	confirm	the	importance	of	
sporulation/germination	patterns	for	pathogenicity	and	transmission.		Most	of	
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the	evaluated	treatment	regimens	for	repeated	CDI	were	effective	in	reducing	
risk	of	an	additional	recurrence,	with	the	effectiveness	varying	by	ribotype.		
However,	we	could	not	detect	a	significant	difference	in	treatment	effectiveness	
between	pulsing	doses	at	48	versus	72	hours.		Furthermore,	treatment	
effectiveness	was	maintained	even	when	the	duration	or	dosage	of	most	of	the	
recommended	regimens	was	reduced.		
	
5.1.0		Introduction	
	
Clostridium	difficile	is	an	anaerobic,	spore‐forming,	Gram‐positive	bacillus	
associated	with	the	toxin‐mediated	intestinal	disease	known	as	C.	difficile	
infection	(CDI)	(1,	2).		CDI	is	one	of	the	leading	reported	causes	of	healthcare‐
associated	infections	in	the	United	States	(US)	(3).	Although	CDI	was	initially	
reported	in	1978,	its	epidemiology	worldwide	has	changed	significantly	in	the	
last	two	decades	(2).	This	change	in	epidemiology	was	initially	attributed	to	the	
emergence	of	a	C.	difficile	ribotype	(ribotype	027)	known	to	have	higher	rates	of	
sporulation	and	toxin	production	(4).	However,	more	recent	studies	have	found	
no	correlation	between	C.	difficile	ribotype	and	clinical	disease	(5‐7).	
Recommended	CDI	treatment	is	a	course	of	oral	metronidazole	or	
vancomycin.		However,	CDI	still	recurs	in	5‐35%	of	patients	following	
appropriate	treatment	(8‐10).		Recurrence	is	defined	as	a	CDI	that	occurs	within	
8	weeks	following	resolution	of	the	initial	episode	(11).		Without	appropriate	
laboratory	testing,	it	is	not	possible	to	determine	if	a	recurrent	case	is	a	relapse	
of	the	same	infection,	a	new	infection	with	a	different	strain,	or	a	new	infection	
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with	the	same	strain	(12).		However,	it	has	been	estimated	that	on	average	half	of	
recurrences	are	due	to	relapse	of	the	original	C.	difficile	strain	(13,	14).	
C.	difficile	spores	that	persist	after	treatment	can	germinate	and	lead	to	
recurrence	(15).	Therefore,	ribotypes	with	higher	sporulation	rates	are	expected	
to	be	associated	with	higher	rates	of	recurrence.		For	example,	ribotype	027,	
known	to	have	a	higher	sporulation	rate,	has	been	reported	as	a	risk	factor	for	
CDI	recurrence	(12,	16).		Similarly,	strains	with	high	germination	efficiency	have	
been	associated	with	severe	and	recurrent	CDI	(14,	17).		
Tapering	or	pulsing	of	oral	vancomycin	is	one	of	the	recommended	
treatments	for	CDI	recurrence,	particularly	for	repeated	recurrent	CDI	(18).		By	
tapering	or	pulsing,	it	is	assumed	that	time	and	a	proper	environment	allow	any	
spores	still	in	the	gut	to	germinate	and	then	be	killed	in	the	vegetative	cell	state.		
Further,	the	regimen	allows	the	microbiota	to	recover	(19,	20).		Although	clinical	
trials	show	tapered/pulsed	vancomycin	treatment	to	be	more	effective	at	
reducing	CDI	recurrence	than	the	standard	longer	and	higher	doses	(20),	no	
controlled	data	exist	evaluating	the	relative	effectiveness	of	the	specific	regimens	
used	for	this	purpose	(21).		
	 We	used	a	mathematical	simulation	model	to	fill	this	gap.		We	simulated	
the	in	vivo	levels	of	spores	and	vegetative	cells	within	the	CDI	host	by	the	four	
most	common	ribotypes	in	the	U.S.	(22)	with	the	initial	purpose	of	determining	
the	importance	of	sporulation/germination	patterns	across	ribotypes	and	their	
contribution	to	the	observed	differences	in	CDI	recurrences.		We	also	evaluated	
the	effectiveness	of	current	tapered/pulsed	vancomycin	regimens	by	ribotype.		
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5.2.0.		Methods	
	
5.2.1.		Deterministic	Ordinary	Differential	Equations	(ODE)	model		
	
We	developed	a	compartmental	in‐host	mathematical	model	for	CDI	
patients,	composed	of	the	major	parts	of	the	bacteria’s	life	cycle	within	the	
human	host:	vegetative	cells,	toxins,	and	spores.	As	our	study	purpose	was	to	
determine	CDI	recurrence,	our	model	simulated	and	measured:	number	of	
vegetative	cells	(C),	viable	spores	(Spl),	non‐viable	spores	(Spd),	and	toxin	(T)	
per	mL	of	gut	contents	per	day.				
Due	to	the	limited	data	available	to	inform	our	overall	model,	the	lack	of	
knowledge	about	the	level	of	simplification	needed	for	the	model	structure,	and	
the	need	to	streamline	model	development	and	parameter	estimation,	we	used	a	
forcing	function	approach	(similar	to	that	developed	in	(23)),	in	which	the	
overall	model	was	broken	into	two	submodels.		The	two	submodels	were:	(1)	
vegetative	cells	and	(2)	spores	and	toxin.		As	illustrated	in	Figure	5.9,	vegetative	
cell	data	define	the	spore	and	toxin	model,	while	vancomycin	concentration	and	
spore	data	define	the	vegetative	cell	model.	We	developed	and	fit	each	submodel	
separately,	combining	the	submodels	for	final	parameter	estimation	from	data,	as	
described	further	below.	
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Vegetative	cell	submodel		
	
Vegetative	cells	are	able	to	proliferate	in	the	colon	if	conditions	are	
permissible.	A	protective	microbiota	and	other	processes	may	inhibit	
colonization	(8).	When	modeling	the	growth	of	C.	difficile	vegetative	cells	(C),	we	
first	considered	the	bacteria’s	growth	rate	(k)	limited	by	their	carrying	capacity	
within	the	human	gut	(Cap).	For	the	logistic	growth	term,	we	tested	several	
exponents,	and	chose	the	lowest	integer	value	that	yielded	a	visually	good	fit	
(cubic	power).		In	addition,	we	considered	the	formation	of	new	cells	due	to	the	
germination	of	available	spores	(kger).		We	also	subtracted	the	loss	of	cells	(kLC),	
either	because	they	sporulated	(ksp)	or	they	were	shed	into	the	environment	
through	feces	(kExC).		Due	to	identifiability	issues,	we	were	unable	to	separate	the	
effects	of	kLC	at	this	point	(where	kLC	=	ksp	+	kExC).		
Finally,	we	considered	the	loss	of	cells	due	to	vancomycin	treatment	(ktxt).		
To	better	represent	the	vancomycin	pharmacokinetics,	we	added	an	extra	
equation	to	this	submodel.		When	using	the	standard	regimen	of	125mg/L	four	
times	a	day,	oral	vancomycin	is	poorly	absorbed,	so	stool	concentrations	
significantly	exceed	the	MIC90	of	most	C.	difficile	isolates	(18,	24).		The	
vancomycin	concentration	(V)	was	first	fitted	to	vancomycin	data	(25)	using	sum	
of	least	of	squares,	then	its	parameter	(kv)	was	fixed	for	the	remainder	of	the	
parameter	fitting.			
The	following	equations	make	up	this	first	submodel:		
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Spores/toxin	submodel	
	
During	its	life	cycle,	C.	difficile	vegetative	cells	produce	endospores	(18).		
Spores	are	highly	resistant	to	immune	system	cells,	antibiotics,	and	harsh	
environmental	conditions	(1,	26).		If	ingested,	spores	survive	the	stomach’s	acid	
environment	and	germinate	in	the	small	intestines	when	stimulated	by	bile	salts	
(1,	26).		Vegetative	cells	of	toxigenic	strains	produce	several	toxins.	Toxin	A	and	
toxin	B	are	most	commonly	associated	with	CDI.	Toxin	A	(TcdA)	is	an	
enterotoxin,	while	toxin	B	(TdB)	is	a	cytotoxin	(1).				
As	vegetative	cells	produce	toxins	and	spores	within	the	gut,	we	modeled	
them	together.		In	order	to	account	for	different	degrees	of	spore	viability	across	
ribotypes,	we	separated	spores	into	two	compartments:	viable	(Spl)	and	non‐
viable	(Spd).	SpV	represents	the	fraction	of	viable	spores	produced	by	ribotype.	
We	further	accounted	for	the	C.	difficile	sporulation	rate	(ksp)	and	the	loss	of	
spores	(kLS)	either	because	they	are	shedded	into	the	environment	through	feces	
(kExSpl/kExSpd)	or	they	germinate	into	vegetative	cells	(kger).		
Similarly,	in	the	toxin	compartment,	we	accounted	for	the	toxin	
production	rate	by	vegetative	cells	(ktox)	and	exit	of	toxin	(kExT),	either	because	it	
was	used	up,	lost	through	feces,	or	decayed.	We	also	incorporated	a	toxin	delay,	
by	a	set	of	slots	(n)	through	which	the	toxin	had	to	pass	before	exiting	the	toxin	
compartment.		The	latter	allowed	us	to	account	for	the	slow	decay	of	the	toxin	in	
the	gut/feces	(27).		The	in‐host	interaction	between	spores	and	toxin	production	
is	described	in	the	following	equations:		
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Submodel	Parameter	Estimation	
	
Both	submodels	were	fitted	using	C.	difficile	ribotype	027	data	from	a	gut	
model	reported	by	Baines	et	al.	2009	(25),	using	sum	of	least	of	squares.		The	
parameters	within	the	vegetative	cells	submodel	were	specifically	fitted	to	the	
vegetative	cells	data,	using	the	spore	data	as	inputs.		Similarly,	the	spore/toxin	
model	was	fitted	to	the	spore	and	toxin	data,	using	the	vegetative	cell	data	from	
(25)	as	an	input.		For	the	model	inputs,	we	used	linear	splines	to	interpolate	
between	data	points,	generating	a	continuous	input	to	each	submodel.		
	
Overall	model		
	
After	individually	fitting	each	submodel,	we	combined	them	to	generate	
the	overall	model	representing	a	CDI	host	(Figure	5.9).		The	overall	model	is	
described	with	the	following	equations	(parameter	details	for	ribotype	027	can	
be	found	in	Table	5.5):		
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5.2.2.		Stochastic	Model		
	
	 As	an	ODE	model	can	only	provide	an	average	of	recurrence	by	ribotype	
and	stochasticity	may	play	an	important	role	during	extinction	or	recurrence	of	
an	infection.	Thus,	we	created	a	stochastic	model	to	estimate	the	probability	of	
recurrence	by	ribotype.		We	focused	on	three	compartments	of	the	overall	ODE	
model:	1)	vegetative	cells,	2)	non‐viable	spores,	and	3)	viable	spores.		As	
vancomycin	concentrations	are	continuous	values	and	unlikely	to	be	stochastic	at	
the	scale	we	are	considering,	we	used	the	same	ODE	representation	for	
vancomycin	treatment	as	in	the	deterministic	model.		We	simulated	the	
vancomycin	concentration	by	treatment	regimen	ahead	of	time	using	a	simple	
model,	which	only	included	the	vancomycin	equation.	The	resulting	datasets	
were	used	to	feed	our	stochastic	model.				
Due	to	the	large	number	of	vegetative	cells	and	spores	that	made	up	our	
system,	we	simulated	our	model	using	the	Tau‐leaping	method	(28).		This	
method	is	similar	to	the	Gillespie	algorithm,	but	it	determines	the	probability	of	
each	event	to	happen	at	each	pre‐specified	interval	of	time,	in	our	case	every	2.4	
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hours	(10	times	a	day).		The	model	estimated	the	probability	of	occurrence	of	5	
specific	events:	1)	vegetative	cell	growth,	2)	germination	of	viable	spores,	3)	exit	
or	death	of	vegetative	cells,	4)	sporulation	of	vegetative	cells,	and	5)	exit	of	viable	
and	non‐viable	spores.		After	each	evaluation,	the	model	added	or	subtracted	
vegetative	cells	or	spores	from	their	specific	compartment	as	needed.		At	the	end	
of	the	simulation,	we	compiled	the	total	number	of	vegetative	cells	and	spores	
(CFU/mL	per	day).		
	
5.2.3.		Simulations	
	
Effect	of	sporulation	rates	and	viability	of	spores	in	CDI	recurrence		
	
The	most	prevalent	ribotypes	currently	circulating	in	the	US	are	ribotype	
027,	002,	014‐020,	and	106	(22).		Thus,	we	based	our	simulations	on	these	four	
ribotypes.		Using	data	from	the	literature	and	the	fitted	parameters	of	our	overall	
model	of	ribotype	027	(Table	5.5),	we	estimated	an	average	rate	of	sporulation	
and	a	fraction	of	viable	spores	for	each	ribotype.	For	example,	using	in	vitro	data	
from	the	literature,	we	estimated	an	average	number	of	spores	produced	per	day	
per	mL	of	40,295	for	ribotype	002,	while	for	027	we	estimated	109,054	spores	
per	day	per	mL.		As	we	knew	the	sporulation	rate	of	027	from	our	model	fit,	we	
were	able	to	solve	for	the	sporulation	rate	of	ribotype	002	
(ksp002=ksp027/(109,054/40,295).	Similarly,	we	solved	for	the	ksp	of	the	other	
ribotypes.		The	fractions	of	the	viable	spores	per	ribotype	were	averaged	from	
the	literature	(5,	7,	17,	29‐32).	The	parameters	are	described	in	Table	5.6.		
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Due	to	the	nature	of	our	ODE	model,	any	fraction	of	vegetative	cells	or	
spores	(even	if	much	less	than	a	single	cell	or	spore)	would	lead	to	
microbiological	recurrence	given	enough	time	to	proliferate,	which	is	not	
consistent	with	nature.	To	conservatively	control	for	this	issue,	we	modified	our	
model	to	indicate	that	if	the	vegetative	cell	or	spore	compartment	had	equal	or	
less	than	0.01%	of	one	cell	or	one	spore,	the	particular	compartment	was	equal	
to	zero.		
We	ran	both	of	our	models	for	a	total	of	200	days.		All	model	parameters	
remained	the	same	as	in	Table	5.5,	except	for	sporulation	rates	and	spore	
viability,	which	we	modified	by	ribotype	(Table	5.6).		On	day	13,	we	added	the	
regular	vancomycin	treatment	(125mg/L	four	times	a	day	for	10	or	14	days)	to	
our	simulation.		The	stochastic	model	was	run	500	times	for	each	ribotype.	
	
Vancomycin	tapered/pulsed‐treatment	effectiveness	against	microbiological	
recurrence	
	
In	this	case,	on	day	13,	we	simulated	three	commonly	used	
tapered/pulsed	vancomycin	treatments	recommended	by	the	Infectious	Diseases	
Society	of	America/	Society	for	Healthcare	Epidemiology	of	America	
(IDSA/SHEA),	and	the	College	of	Gastroenterology	(ACG).		In	addition,	we	
included	an	alternate	regimen	based	on	clinical	expertise	(33)	(Figure	5.10).		
	IDSA/SHEA	2010	recommendations	for	recurrent	CDI	include	oral	
vancomycin	125mg/L	four	times	daily	for	10‐14	days	(we	simulated	14	days	
instead	of	10,	in	order	to	be	more	conservative),	followed	by	vancomycin	twice	a	
day	for	a	week,	then	vancomycin	once	daily	for	one	week,	concluding	with	
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vancomycin	every	48‐72	hours	for	2‐8	weeks	(18).		Similarly,	ACG	recommends	
125	mg/L	4	times	a	day	for	10	days	followed	by	every	72	hours	for	ten	doses	
(21).		Finally,	a	recent	published	review	recommends	based	on	expert	opinion	an	
alternate	regimen	described	as	follows:	125mg/L	four	times	daily	for	1‐2	weeks,	
then	125mg/L	three	times	a	day	for	1	week,	followed	by	125mg/L	twice	a	day	for	
1	week,	then	125mg/L	once	daily	for	1	week,	next	125mg/L	every	48	hours	for	1	
week,	and	concluding	with	125mg/L	every	72	hours	for	1	week	(33)	(Figure	
5.10).			
In	addition,	we	tested	the	SHEA/IDSA	recommended	regimens,	omitting	
the	initial	regular	treatment	(125	mg/L	four	times	a	day	for	10‐14	days).		
Similarly,	we	experimented	with	the	alternate	regimen	removing	the	initial	
regular	treatment	of	oral	vancomycin	four	times	a	day	for	1‐2	weeks.		We	further	
tested	a	modified	ACG	regimen	by	1)	reducing	the	number	of	pulsed	doses	and	2)	
reducing	the	vancomycin	dose	from	125mg/L	4	times	a	day	to	twice	a	day	
(Figure	5.10).			
Similarly	to	previous	simulations,	we	modified	our	ODE	model	to	indicate	
the	same	minimal	threshold	for	the	vegetative	cell	or	spore	compartments.		The	
stochastic	model	was	run	500	times	for	each	ribotype	per	regimen.		
	
Sensitivity	analysis	
	
	 The	recommended	vancomycin	regimen	of	125mg/L	four	times	a	day	
achieves	vancomycin	fecal	levels	several	hundred	times	higher	than	the	
vancomycin	MIC90	for	C.	difficile	(24).		Thus,	our	model’s	ability	to	fit	the	
vancomycin‐killing	rate	is	limited,	as	the	vancomycin	regimen	kills	all	C.	difficile	
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vegetative	cells	very	quickly.		In	order	to	assure	a	proper	fitting	of	this	
parameter,	we	ran	our	stochastic	model	using	an	upper	(1.8)	and	lower	
threshold	(1.3)	of	ktxt	values.		We	chose	these	thresholds	because	they	were	the	
largest	and	smallest	values	that	yielded	a	visually	nearly	indistinguishable	fit	to	
the	data.		We	ran	our	simulations	1000	times	with	these	values	to	validate	our	
model	and	guarantee	its	agreement	with	available	literature	on	recurrence	rates.			
	
5.3.0.		Results		
	
5.3.1.		Overall	Model		
	
Our	overall	model	simulates	the	pathogenicity	and	transmission	patterns	
of	C.	difficile	within	its	human	host	(Figure	5.9	and	5.11).		The	final	model	
parameters	are	described	in	Table	5.5	and	5.6.		
	
5.3.2.		Simulations	
	
Effect	of	sporulation	rates	and	viability	of	spores	on	CDI	recurrence	
	
As	expected,	sporulation	rates	and	viability	of	spores	affected	
pathogenicity	and	transmission	patterns	in	vivo	(Figure	5.12).		Using	the	
deterministic	model,	all	ribotypes	but	014‐020	recurred	after	10	days	of	125	
mg/L	four	times	a	day.	Ribotype	014‐020	was	able	to	cause	a	first	CDI	episode,	
but	treatment	was	enough	to	control	the	bacteria	within	the	gut	and	avoid	a	
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recurrence.		By	contrast,	ribotypes	(027,	106,	002)	were	able	to	recur	
approximately	30‐55	days	after	initial	CDI	treatment.		Notably,	the	levels	of	
spores	were	quite	diverse.		For	example	at	day	55,	spore	levels	ranged	from	626	
to	4.4x104	CFU/mL.		However,	when	we	extended	the	regular	treatment	to	14	
days,	ribotype	002	was	also	unable	to	recur.			
In	our	stochastic	model,	all	of	the	ribotypes	recurred	in	at	least	one	
simulation	after	10	days	of	treatment.		However,	the	probability	of	recurrence	
varied	by	ribotype:	ribotype	106	(18.8%),	ribotype	027	(12.2%),	ribotype	002	
(6.8%),	and	014‐020	(1.0%)	(Figure	5.12).	This	matches	the	more	binary	results	
seen	in	the	deterministic	model,	with	a	more	nuanced	outcome.			Similarly,	when	
we	extended	treatment	4	extra	days	(14	days	total),	the	probability	of	recurrence	
was	reduced	even	further:	ribotype	106	(4.0%),	ribotype	027	(4.0%),	ribotype	
002	(1.2%),	and	014‐020	(0%)	(Figure	5.12).		
	
Vancomycin	tapered/pulsed‐treatment	effectiveness	against	microbiological	
recurrence	
	
All	of	the	recommended	vancomycin	tapered/pulsed	regimens	for	
treating	repeated	CDI	were	effective	in	avoiding	recurrence	from	all	ribotypes.		
Moreover,	2	weeks	of	vancomycin	pulses	(either	at	48	or	72	hours)	as	part	of	the	
SHEA/IDSA	regimen	were	enough	to	avoid	recurrence.		Similarly,	one	week	of	
the	regular	oral	vancomycin	regimen	(125mg/L	four	times	a	day)	at	the	
beginning	of	the	simulated	alternate	regimen	was	sufficient	to	avoid	future	
relapses	(Table	5.7).			
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We	proceeded	to	perform	further	modifications	to	the	recommended	
regimens.		For	the	SHEA/IDSA	regimen,	when	we	completely	skipped	the	initial	
regular	treatment	(125mg/L	four	times	a	day	for	14	days),	we	observed	the	
regimen	was	totally	effective	for	all	ribotypes	after	only	four	weeks	of	pulsed	
doses.		However,	this	modification	with	only	two	weeks	of	pulsing	every	48	
hours	was	effective	for	all	but	ribotype	027,	which	recurred	0.2%	of	the	time.		
Interestingly,	if	instead	we	pulsed	every	72	hours	for	2	weeks,	both	ribotype	027	
and	ribotype	106	recurred	but	also	at	low	levels	(0.2‐0.6%).		Similarly	in	the	
alternate	tested	regimen,	when	we	eliminated	the	2	initial	weeks	of	125mg/L	of	
oral	vancomycin	four	times	daily,	we	still	did	not	observe	any	recurrences	for	
any	of	the	ribotypes.		When	we	reduced	the	ACG	pulsed	doses	to	7	(every	
72hours),	the	regimen	remained	effective	at	avoiding	recurrence	from	all	
ribotypes.		Furthermore,	when	we	reduced	the	dose	to	125mg/L	twice	a	day	for	
10	days	followed	by	pulses	every	72	hours	for	10	doses;	the	treatment	was	still	
effective,	with	only	ribotype	27	recurring,	and	at	a	very	low	rate	(0.2%	
recurrence)	(Table	5.7).		
	
Sensitivity	analysis		
	
To	assess	the	sensitivity	of	our	assessments,	we	ran	the	same	simulations	
but	modified	the	killing	rate	by	an	upper	or	lower	threshold,	which	yielded	
nearly	identical	results	(recurrence	rates	with	the	alternate	values	were	all	
within	2.5%	of	the	recurrence	rates	using	the	fitted	value	of	ktxt).	
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5.4.0.		Discussion	
	
We	used	a	compartmental	in‐host	mathematical	model	for	CDI	patients	to	
simulate	in	vivo	toxin	and	spore	rates	for	the	most	prevalent	C.	difficile	ribotypes	
and	evaluate	whether	ribotype‐specific	sporulation/germinations	patterns	affect	
CDI	recurrence	and	effectiveness	of	treatment	regimens	for	reducing	risk	of	
repeated	recurrence.		All	the	recommended	treatment	regimens	were	effective	in	
reducing	risk	of	an	additional	recurrence.	Furthermore,	reducing	the	duration	or	
dosage	of	most	of	the	assessed	regimens	did	not	change	effectiveness.		
Our	simulations	confirm	that	differences	in	sporulation/germination	
patterns	across	C.	difficile	ribotypes	are	risk	factors	for	recurrence.	Ribotype	014‐
020	has	higher	spore	viability	but	lower	sporulation	rates	than	the	other	
ribotypes	evaluated,	and	recurred	up	to	1.0	%	of	the	time	following	initial	CDI	
treatment	with	vancomycin,	much	less	frequently	than	other	ribotypes.		Indeed,	
although	this	ribotype	does	recur,	it	accounts	for	only	5%	of	CDI	recurrences	in	
North	America	(34).	Moreover,	these	results	suggest	that	the	CDI	recurrence	rate	
can	be	explained	by	differences	in	sporulation	and	germination	patterns	by	
ribotype,	which	also	validates	the	model’s	predictive	ability.		In	addition,	our	
model	highlights	the	benefit	of	a	longer	initial	CDI	treatment,	that	is	14	days	
instead	of	10	days,	in	order	to	reduce	the	likelihood	of	an	initial	CDI	recurrence.			
If	we	consider	the	reported	distribution	of	ribotypes	found	in	hospital	and	
community‐associated	CDI	cases	(22)	and	our	recurrence	rates,	ribotypes	027,	
002,	014‐020,	and	106	would	lead	to	a	combined	recurrence	rate	of	3‐11%	
(depending	on	the	duration	of	initial	treatment),	which	overlaps	with	the	
recurrence	range	of	5‐35%	reported	in	the	literature	(8‐10).		Nevertheless,	the	5‐
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35%	range	includes	relapses	and	reinfections	by	the	same	or	different	strains,	
and	our	estimate	includes	only	relapses	from	the	same	strain.		Relapses	
reportedly	account	for	25	to	87.5%	of	all	recurrences	(14)	(i.e.	there	is	a	~1‐31%	
rate	of	relapse	among	initial	CDI	cases),	which	is	also	consistent	with	our	results.		
	 In	our	models,	all	the	recommended	treatment	regimens	for	repeated	CDI	
recurrence	were	highly	effective	in	avoiding	an	additional	recurrence,	which	is	
validated	by	the	fact	that	only	up	to	6%	of	CDI	cases	recurred	2	or	more	times	
(35).		Our	models	also	suggest	that	there	is	no	significant	difference	in	treatment	
efficacy	between	pulsing	periods	of	48	or	72	hours	when	applied	to	the	regimens	
as	they	are	currently	recommended.		However,	the	regimens	could	be	reduced	in	
duration	or	in	dosage	and	still	be	highly	effective.				
This	finding	has	potentially	important	clinical	implications,	as	vancomycin	
therapy	is	not	without	risk.		Vancomycin	treatment	suppresses	Bacteriodes	spp.,	
a	marker	of	normal	gut	microbiota	(36),	and	a	healthy	gut	microbiota	prevents	
the	introduction	or	colonization	of	pathogens,	including	the	reemergence	of	C.	
difficile	(37).		Furthermore,	vancomycin	and	similar	anti‐anaerobic	therapy	can	
promote	the	selection	and	spread	of	vancomycin‐resistant	enterococcus	
colonization	(37,	38).		Our	results	suggest	that	vancomycin	regimens	might	be	
further	modified	to	a	level	that	better	protects	gut	microbiota	while	preventing	
CDI	recurrence,	although	this	can	only	be	definitely	answered	using	appropriate	
controlled	clinical	trials.		In	addition,	studies	examining	the	role	of	probiotics	in	
conjunction	with	tapered/pulsed	vancomycin	may	uncover	potential	regimens	to	
reduce	the	vancomycin	dosage	and	duration	even	further.			
Similarly,	our	model	results	support	the	potential	of	tailoring	initial	CDI	
treatment	based	on	the	causative	C.difficile	ribotype.		Patients	diagnosed	as	
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having	CDI	due	to	ribotype	027	are	more	susceptible	to	recur;	thus,	physicians	
may	decide	to	follow	these	patients	more	closely	to	early	identify	CDI	recurrence.		
Moreover,	these	patients	may	benefit	from	an	initial	tapered/pulse	oral	
vancomycin	treatment	instead	of	the	regular	higher	dosed	treatment	usually	
given	as	CDI	initial	treatment.			However,	it	is	essential	to	consider	host	risk	
factors	and	biological	markers	in	conjunction	with	CDI	ribotype	to	better	
customize	CDI	treatment.			
As	with	any	simulation	study,	our	model	is	limited	by	the	current	state	of	
knowledge	and	data	available	to	inform	the	model.		C.	difficile	vegetative	cells,	
spores	and	even	toxin	are	found	among	asymptomatic	individuals	(39);	thus	our	
model	could	not		distinguish	between	C.	difficile	colonization	and	symptomatic	
CDI	recurrence.		We	did	not	include	the	effects	of	host	factors	that	might	directly	
influence	C.	difficile	sporulation	and	toxin	production	in	our	model,	as	there	is	
limited	in	vivo	human	data	available.		Similarly,	our	model	does	not	account	for	
biofilm	formation	within	the	human	gut,	which	could	potentially	decrease	CDI	
treatment	effectiveness	and	increase	CDI	recurrence	(40).		In	addition,	our	
models	do	not	account	for	inter‐strain	variation	of	sporulation	and	germination	
patterns	across	ribotypes,	which	have	been	observed	in	in	vitro	and	gut	models	
(7,	25,	30,	31,	41,	42).		Finally,	this	study	does	not	include	other	potential	
recommended	treatments	for	recurrent	CDI,	such	as	fidaxomicin	(33).			
In	conclusion,	we	developed	a	compartmental	in‐host	mathematical	
model	of	CDI.		Our	results	highlight	the	importance	of	sporulation/germination	
patterns	across	C.	difficile	ribotypes	on	CDI	pathogenicity	and	transmission,	
which	directly	affects	CDI	treatment	and	infection	control.		Current	CDI	
vancomycin	regimens	particularly	for	treating	recurrent	cases	should	be	further	
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studied	to	better	balance	their	associated	risks	and	benefits.		More	broadly,	this	
model	provides	a	tool	to	explore	the	role	of	the	human	host	in	C.	difficile	
colonization,	infection,	recurrence	and	transmission.		
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Table	5.5.		Final	overall	model	parameters	for	ribotype	027.	These	parameters	
were	used	to	feed	our	simulations	for	all	ribotypes,	the	sporulation	rates	(ksp)	
and	fraction	of	viable	spores	(SpV)	were	the	only	parameters	that	were	modified	
based	on	the	ribotype	across	our	model	simulations.			
	
Model	Parameter	 Description Value	
N	 Number	of	toxin	delay	
compartments		
2	
K	 C.	difficile growth	rate	
(cells/day)	
1.1953	
Cap	 Carriage	capacity	
(cells/day)	
1.2241x106	
	
ksp	 Sporulation	rate	(1/day) 0.0072	
SpV	 Fraction	of	viable	spores	
(1/day)	
0.534050	
kger	 Germination	rate	
(1/day)	
0.0006	
ktox	 Toxin	production	rate	
(1/day)	
0.0043	
kExC	 Exit	rate	of	vegetative	cells	
(1/day)	
0.0352	
kExSpd	 Exit	rate	of	dead	spores	
(1/day)	
0.3577	
kExSpl	 Exit	rate	of	alive	spores	
(1/day)	
0.3197	
KExT	 Exit	rate	of	toxin	(1/day) 0.3164	
Ktxt	 Treatment	killing	rate	(vc	
killed/day)	
1.5811	
kv	 Exit	rate	of	vancomycin		
(1/day)	
1.3116	
u(t)	 Vancomycin	input	 Simulation	
dependent	
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Table	5.6.		Sporulation	rates,	spore	viability,	and	data	source	by	selected	
ribotypes	used	to	inform	the	in‐host	model	of	Clostridium	difficile	infection			
	
Simulation	Parameters	
Sporulation	rates	by	
ribotype	
Spores/day	per	
mL	
Sporulation	rate	
((spores/day)/mL)	
Sources	used	
			027	 109,054 (5,	7,	29,	30,	32)
			002	 40,295 0.002665654 (7,	30)
			106	 184,555 0.012208954  (7,	30)
			014‐020		 2,773 0.000183444 (5)	
Spore	viability	by	ribotype	 Fraction	of	spore	viability	 Sources	used
			027	 0.5341 (5,	17,	31)
			002	 0.4700 (31)	
			106	 0.4151 (17)	
			014‐020		 0.6276 (5,	31)
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Table	5.7.		Recurrence	rate	by	ribotype	after	receiving	recommended	or	
modified	oral	vancomycin	tapered/pulsed	regimens.			
	
Regimen	 Ribotypes	
	 106 027 002	 014‐020
Commonly	used	regimens 	
SHEA/IDSA:	pulses	every	48h	for	2	
weeks	
0% 0% 0%	 0%	
Alternate	regimen:	pulses	every	
72hr	for	2	weeks	
0% 0% 0%	 0%	
Alternate	regimen:	with	only	1	week	
of	125	mg/L	four	times	a	day		
0% 0% 0%	 0%	
ACG:	Full	regimen		 0% 0% 0%	 0%	
Modifications	 	
SHEA/IDSA:	without	initial	regular	
txt	+	72hr	pulses	for‐2weeks	
0.6% 0.2% 0%	 0%	
SHEA/IDSA:		without	initial	regular	
txt	+	48hr	pulses	for	2	weeks	
0% 0.2% 0%	 0%	
SHEA/IDSA:	without	initial	regular	
txt	+	72hr	pulses	for	4	weeks	
0% 0% 0%	 0%	
SHEA/IDSA:	without	initial	regular	
txt	+	48hr	pulses	for	4	weeks	
0% 0% 0%	 0%	
Alternate	regimen:	without	initial	
regular	treatment	(125	mg/L	four	
times	a	day	for	2	weeks)		
0% 0% 0%	 0%	
ACG:	125mg/L	twice	a	day+10	
pulsed	doses		
0% 0.2% 0%	 0%	
ACG:	125	mg/L	4	times	a	day	+	only	
7	pulsed	doses	
0% 0% 0%	 0%	
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Figure	5.9.		Graphical	representation	of	the	overall	in‐host	compartmental	CDI	
model	within	its	human	host.	Upper	rectangle	(dotted‐lines)	represents	the	
vegetative	cells	submodel.		Lower	rectangle	(dashed‐lines)	represents	the	
spore/toxin	submodel.	
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A.	Recommended	regimens		
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B.	Modified	regimens	
	
	
Figure	5.10.		Graphical	representation	of	tested	A)	recommended	
tapered/pulsed	oral	vancomycin	regimens	and	B)	modified	recommended	
regimens.			We	tested	three	specific	regimens:	one	recommended	by	The	Society	
for	Healthcare	Epidemiology	of	America	(IDSA/SHEA),	another	by	the	American	
College	of	Gastroenterology	(ACG),	and	the	third	one	is	an	alternate	regimen	
based	on	expert	opinion	(33).		The	gray‐colored	blocks	represent	optional	steps,	
and	the	dotted‐lined	blocks	represent	the	steps	that	were	eliminated	or	modified	
for	the	purposes	of	this	study.		
Abbreviations:	w=week,	hr=	hour	
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Figure	5.11.		Fitting	of	overall	in‐host	compartmental	model	of	CDI	within	the	
symptomatic	host	(Ribotype	027).	Circles	indicate	the	data	used	for	fitting	(25)	
and	solid	line	is	the	fitted	model.		
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Treatment	duration		 	
	 	 10	days		 	 	 	 	 	 	 	 	14	days	 	 	
C.		Ribotype	002	(1.2‐6.8%	recurrence)		 	 					 	 	 	
					 	
D.		Ribotype	014‐020	(0‐1.0%	recurrence)		
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Figure	5.12.		Simulated	recurrence	rate	by	ribotype:	differences	on	sporualation	rates	and	fraction	of	viable	spores	per	ribotype	are	
reflected	on	differences	on	recurrence	rates.	On	day	13	post	infection,	we	added	to	the	model	the	regular	vancomycin	CDI	treatment	
:125mg/L	four	times	a	day	for	10	days	(left)	or	125mg/L	four	times	a	day	for	14	days	(right).		The	black	solid	lines	represent	each	of	the	
500	runs	of	the	stochastic	model,	and	the	white	slashed‐line	represents	the	results	of		our	deterministic	model.	
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CHAPTER	VI	
Conclusions		
	
Clostridium	difficile	is	indeed	a	difficult	organism.		Although	the	last	
decades	have	increased	understanding	of	its	biology,	pathogenicity,	and	
transmission,	C.	difficile	remains	one	of	the	most	reported	causes	of	nosocomial	
infection	in	the	United	States	and	around	the	world.		Furthermore,	C.	difficile	
infection	(CDI)	has	spread	to	community	settings	and	now	infects	individuals	
previously	considered	low‐risk.		
This	dissertation	provides	new	insights	into	the	pathogenicity	and	
transmission	patterns	of	C.	difficile	within	its	human	host.	Although	much	
research	has	been	done	on	CDI,	much	of	the	research	has	used	animal	or	gut	
models.		Research	using	clinical	samples	directly	without	the	intermediate	‘in	
vitro’	component	to	approximate	the	sporulation	and	toxin	production	of	C.	
difficile	isolates	is	less	common.		The	primary	goal	of	this	dissertation	was	to	
provide	in	vivo	CDI	insights	and	to	apply	them	to	three	specific	areas:	1)	infection	
control	and	prevention,	2)	diagnosis,	and	3)	treatment.				
	 The	main	goal	of	our	first	study	was	to	characterize	the	in	vivo	association	
of	C.	difficile	spore	and	toxin	production	and	their	association	with	the	presence	
of	Candida	albicans.		We	observed	a	strong	positive	association	between	C.	
difficile	toxin	and	spore	levels,	with	the	association	varying	slightly	by	ribotype.		
Consistent	with	this	finding,	toxin	negative/PCR	positive	stool	samples	had	
		 120
significantly	fewer	spores	than	toxin	positive	CDI	ones.		However,	contrary	to	our	
hypothesis,	the	presence	of	C.	albicans	did	not	modify	these	associations	in	our	
study	population.		Nevertheless,	ribotypes	027	and	078	were	significantly	
associated	with	high	levels	of	toxin	and	spores	and	C.	albicans	overgrowth	in	the	
gut.			
The	absence	of	a	C.	difficile	spore‐toxin	trade	off	within	its	human	host	
suggests	that	spore	production	may	enhance	pathogenicity	as	well	as	
transmission.		This	conclusion	has	important	implications	for	CDI	infection	
control	and	prevention.		A	spore‐toxin	association	implies	that	more	severe	
cases,	which	are	expected‐‐although	this	is	still	controversial‐‐	to	have	larger	
amounts	of	toxin,	will	also	be	shedding	larger	amounts	of	spores.		This	highlights	
the	importance	of	timely	CDI	patient	isolation.		Additionally,	it	suggests	that	extra	
precautions	should	be	taken	when	dealing	with	CDI	patients	in	the	ICU	or	other	
high‐risk	settings.		
Our	second	study	aimed	to	better	understand	the	clinical	and	
epidemiological	differences	between	CDI	patients	according	to	their	laboratory	
diagnosis.		We	investigated	if	the	differences	that	previous	authors	had	reported	
were	maintained	among	a	population	with	high	CDI	treatment	rates.	Like	
previous	investigators,	we	observed	that	toxin	negative	PCR	positive	patients	
had	a	less	severe	CDI	presentation	than	toxin	positive	patients.		In	addition,	we	
identified	a	strong	association	between	white	race	and	a	toxin	positive	CDI	
diagnosis,	which	was	maintained	even	after	controlling	for	known	CDI	risk	
factors.		Providing	further	evidence	to	support	these	differences	by	CDI	
laboratory	diagnosis	confirms	the	need	to	revise	and	standardize	the	current	
laboratory	algorithms	in	the	US.			
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	 In	this	same	study,	we	also	sought	to	identify	host‐risk	factors	associated	
with	fecal	spore	levels.		Spore	levels	were	strongly	associated	with	CDI	severity	
and	known	CDI	risk	factors	such	as	previous	history	of	antibiotics,	proton	pump	
inhibitors,	and	previous	hospitalization.		These	results	support	the	conclusions	
from	our	first	study,	that	the	more	severe	CDI	presentation,	the	more	spores	are	
shed.		Healthcare	workers	should	be	aware	that	these	patients	are	more	
infectious	and	that	already	established	precautions	should	be	followed	strictly	
and	even	heightened	when	dealing	with	patients	with	severe	CDI.			
In	our	third	study,	we	aimed	to	develop	an	in‐host	mathematical	model	to	
simulate	the	in	vivo	toxin	and	spore	levels	within	its	human	host.		We	created	
both	a	deterministic	and	stochastic	version	of	a	compartmental	model	to	
determine	the	role	of	sporulation	and	germination	patterns	in	recurrence	and	
the	effectiveness	of	current	tapered/pulsed	vancomycin	regimens	by	ribotype.		
All	of	the	evaluated	treatment	regimens	for	repeated	CDI	were	effective	in	
reducing	risk	of	an	additional	recurrence,	with	the	effectiveness	varying	by	
ribotype,	and	thus	by	their	sporulation	and	germination	patterns.		Furthermore,	
treatment	effectiveness	was	maintained	even	when	the	duration	or	dosage	of	
most	of	the	assessed	regimens	was	reduced.		These	results	highlight	that	
tapered/pulsed	vancomycin	regimens	might	be	further	modified	to	a	level	that	
better	protects	gut	microbiota	while	preventing	CDI	recurrence.		
These	results	suggest	several	lines	for	future	research.		Future	laboratory	
studies	should	elucidate	how	spore	and	toxin	production	are	linked	in	C.	difficile	
and	identify	bacterial	and	host	signals	regulating	their	productions	in	vivo.		
Clinical	studies	are	needed	to	improve	our	understanding	of	the	role	played	by	
asymptomatic	carriers	in	healthcare	and	community	settings.		Prospective	
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longitudinal	studies	are	warranted	to	clarify	the	significance	of	asymptomatic	
carriers	in	CDI	transmission.		Our	in‐host	mathematical	model	could	be	modified	
to	further	elucidate	the	role	of	asymptomatic	carriers.		In	addition,	more	
investigation	is	necessary	to	identify	if	there	is	a	racial/genetic	predisposition	to	
CDI	or	if	race	is	acting	as	a	proxy	of	a	group	of	other	independents	CDI	
predictors.		A	larger,	more	representative	study	that	incorporates	racial	groups	
other	than	whites	and	blacks,	and	includes	further	data	such	as	ethnicity	and	
nativity,	will	be	required.			Furthermore,	a	cost‐effectiveness	analysis	of	the	use	
of	molecular	tests	as	part	of	the	CDI	laboratory	diagnosis	should	be	performed.		
This	study	is	essential	for	estimating	the	economic,	social,	and	clinical	impact	of	
including	PCR	as	part	of	the	diagnosis.			Finally,	further	controlled	clinical	trials	
are	necessary	to	improve	CDI	treatment	regimens	to	minimize	CDI	recurrence	
and	to	lessen	gut	microbiota	disturbance.			
	 Collectively	this	dissertation	demonstrates	the	importance	of	considering	
the	pathogen	and	the	human	host	together	when	researching	CDI.		In	our	first	
study,	we	demonstrated	that	the	toxin‐spore	correlation	in	vivo	is	different	than	
the	one	previously	observed	in	vitro.		Similarly,	in	our	second	study,	we	identified	
the	importance	of	the	patient’s	clinical	presentation	when	receiving	a	toxin	
negative	PCR	positive	result.		Finally,	in	our	third	study	we	demonstrated	the	
importance	of	C.	difficile	sporulation	and	germination	patterns	for	CDI	recurrence	
and	thus,	for	the	effectiveness	of	CDI	treatment.		Thinking	of	CDI	as	a	
multifactorial	disease	promises	to	be	an	effective	path	towards	managing,	and	
controlling	and	preventing	CDI.	
	
